

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 10-Q

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2008

OR

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission file number 000-32085

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

36-4392754
(I.R.S. Employer
Identification Number)

222 Merchandise Mart, Suite 2024
Chicago, IL 60654
(Address of principal executive offices)

(866) 358-6869
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 31, 2008, there were 145,905,129 shares of the registrant's \$0.01 par value common stock outstanding.

[Table of Contents](#)

Explanatory Note

On October 10, 2008, Allscripts Healthcare Solutions, Inc. (which changed its name to Allscripts-Misys Healthcare Solutions, Inc. on October 10, 2008, “Allscripts”) completed the transactions (the “Transactions”) contemplated by an Agreement and Plan of Merger dated as of March 17, 2008 by and among Misys plc, Misys Healthcare Systems, LLC (“MHS”), Allscripts and Patriot Merger Company, LLC. The Transactions are described in greater detail in this Form 10-Q. As a result of the Transactions, MHS became a wholly-owned subsidiary of Allscripts and Allscripts changed its fiscal year to end on May 31. This Quarterly Report on Form 10-Q relates only to legacy Allscripts Healthcare Solutions Inc. and, as such, does not include any results of operations of MHS. Since the Transactions constituted a “reverse acquisition” for accounting purposes, the pre-acquisition combined financial statements of MHS will be treated as the historical financial statements of Allscripts going forward and will be included in Allscripts’ Quarterly Report on Form 10-Q for the quarter ending November 30, 2008.

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.

**FORM 10-Q
INDEX**

	<u>PAGE</u>
<u>PART I. FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements (unaudited)</u>	
<u>Consolidated Balance Sheets at September 30, 2008 and December 31, 2007</u>	3
<u>Consolidated Statements of Operations for the three and nine months ended September 30, 2008 and 2007</u>	4
<u>Consolidated Statements of Cash Flows for the nine months ended September 30, 2008 and 2007</u>	5
<u>Notes to Consolidated Financial Statements</u>	6
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	18
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	25
<u>Item 4. Controls and Procedures</u>	25
<u>PART II. OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	25
<u>Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities</u>	26
<u>Item 4. Submission of Matters to a Vote of Security Holders</u>	26
<u>Item 5. Other Information</u>	26
<u>Item 6. Exhibits</u>	26
<u>SIGNATURES</u>	27

PART I. FINANCIAL INFORMATION**Item 1. Financial Statements****ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)**

	September 30, 2008 (unaudited)	December 31, 2007
ASSETS		
Current assets:		
Cash and cash equivalents	\$71,189	\$43,785
Marketable securities	5,435	5,759
Accounts receivable, net of allowances of \$5,073 and \$4,190 at September 30, 2008 and December 31, 2007, respectively	95,560	81,351
Deferred taxes, net	5,459	16,650
Inventories	5,193	4,178
Prepaid expenses and other current assets	17,947	17,401
Total current assets	200,783	169,124
Long-term marketable securities	2,845	13,459
Fixed assets, net	20,297	18,238
Software development costs, net	22,951	24,115
Intangible assets, net	96,983	107,503
Goodwill	247,556	240,452
Other assets	3,982	5,252
Total assets	<u>\$595,397</u>	<u>\$578,143</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$13,360	\$15,911
Accrued expenses	22,683	17,266
Accrued acquisition obligation	—	8,946
Accrued compensation	6,524	5,441
Deferred revenue	54,325	45,940
Current portion of long-term debt	296	279
Other current liabilities	—	274
Total current liabilities	97,188	94,057
Long-term debt	134,938	135,162
Deferred taxes, net	8,177	6,179
Other liabilities	1,834	2,105
Total liabilities	242,137	237,503
Preferred stock:		
Undesignated, \$0.01 par value, 1,000 shares authorized, no shares issued and outstanding at September 30, 2008 and December 31, 2007	—	—
Common stock:		
\$0.01 par value, 150,000 shares authorized; 57,428 issued and outstanding at September 30, 2008; 56,918 issued and outstanding at December 31, 2007	574	569
Additional paid-in capital	859,739	853,402
Accumulated deficit	(506,794)	(513,242)
Accumulated other comprehensive loss	(259)	(89)
Total stockholders' equity	353,260	340,640
Total liabilities and stockholders' equity	<u>\$595,397</u>	<u>\$578,143</u>

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Revenue:	(Unaudited)			
Software and related services	\$71,813	\$58,985	\$198,610	\$164,906
Prepackaged medications	9,991	10,904	29,079	32,072
Total revenue	81,804	69,889	227,689	196,978
Cost of revenue:				
Software and related services	33,049	25,017	88,935	70,196
Prepackaged medications	8,384	9,223	23,845	26,672
Total cost of revenue	41,433	34,240	112,780	96,868
Gross profit	40,371	35,649	114,909	100,110
Selling, general and administrative expenses	32,605	25,977	94,748	71,548
Amortization of intangible assets	3,439	2,757	10,317	7,909
Income from continuing operations	4,327	6,915	9,844	20,653
Interest expense	(1,560)	(927)	(4,587)	(2,790)
Interest income and other, net	128	934	1,070	3,077
Gain on sale of equity investment	—	—	—	2,392
Income from continuing operations before income taxes	2,895	6,922	6,327	23,332
Provision for income taxes	1,123	2,770	2,460	9,317
Net income from continuing operations	\$1,772	\$4,152	\$3,867	\$14,015
Income (Loss) from discontinued operations (includes net gain on disposal of \$1,985 for the three and nine months ended September 30, 2008, net of tax)	2,244	(28)	2,581	604
Net income (loss) from discontinued operations	\$2,244	(\$28)	\$2,581	\$604
Net income	\$4,016	\$4,124	\$6,448	\$14,619
Net income per share from continuing operations—basic	\$0.03	\$0.07	\$0.07	\$0.25
Net income per share from continuing operations—diluted	\$0.03	\$0.07	\$0.07	\$0.24
Net income per share from discontinued operations—basic	\$0.04	\$0.00	\$0.04	\$0.01
Net income per share from discontinued operations—diluted	\$0.04	\$0.00	\$0.04	\$0.01
Weighted-average shares of common stock outstanding used in computing basic net income per share	57,008	56,191	56,763	55,500
Weighted-average shares of common stock outstanding used in computing diluted net income per share	58,201	65,225	57,784	64,541

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

	Nine Months Ended	
	September 30,	
	2008	2007
Cash flows from operating activities:		
Net income from continuing operations, net of tax	\$3,867	\$14,015
Net income from discontinued operations, net of tax	2,581	604
Net income	<u>\$6,448</u>	<u>\$14,619</u>
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	22,276	15,090
Stock-based compensation expense	5,251	2,790
Gain on sale of equity investment	—	(2,392)
Realized loss on investments	13	41
Provision for doubtful accounts	3,723	1,787
Deferred taxes	3,691	8,425
Gain on sale of Physicians Interactive business	(3,253)	—
Changes in operating assets and liabilities:		
Accounts receivable	(22,941)	(27,514)
Inventories	(1,015)	(1,123)
Prepaid expenses and other assets	518	(7,055)
Accounts payable	(2,278)	5,393
Accrued expenses	4,467	(2,669)
Accrued compensation	1,083	(4,471)
Deferred revenue	11,807	5,535
Other current liabilities	(753)	59
Net cash provided by operating activities	<u>29,037</u>	<u>8,515</u>
Cash flows from investing activities:		
Capital expenditures	(7,135)	(6,113)
Capitalized software	(8,760)	(10,104)
Purchase of marketable securities	—	(17,485)
Sales and maturities of marketable securities	10,755	15,043
Sale of equity investment	—	2,592
Net payments for purchase of Extended Care Information Network, Inc.	(9,660)	—
Net payments for purchase of A4 Health Systems, Inc.	—	(265)
Net payments for other acquisitions and related transaction costs	—	(11,331)
Net proceeds from sale of Physicians Interactive business	11,104	—
Net cash used in investing activities	<u>(3,696)</u>	<u>(27,663)</u>
Cash flows from financing activities:		
Proceeds from exercise of common stock options	1,494	7,990
Proceeds from employee stock purchase plan, net	569	665
Net cash provided by financing activities	<u>2,063</u>	<u>8,655</u>
Net increase (decrease) in cash and cash equivalents	27,404	(10,493)
Cash and cash equivalents, beginning of period	<u>43,785</u>	<u>42,461</u>
Cash and cash equivalents, end of period	<u>\$71,189</u>	<u>\$31,968</u>

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited, dollar and share amounts in thousands, except per-share amounts)

1. Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission ("SEC"). The interim consolidated financial statements include the consolidated accounts of Allscripts-Misys Healthcare Solutions, Inc. and its wholly-owned subsidiaries ("Allscripts" or the "Company") with all significant intercompany transactions eliminated. In management's opinion, all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to SEC rules and regulations. These financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2007, in Allscripts' Annual Report on Form 10-K, filed with the SEC on February 29, 2008. Operating results for the three and nine months ended September 30, 2008 are not necessarily indicative of the results for the full year. Certain of the 2007 amounts in the accompanying financial statements have been reclassified to conform to the presentation in this report.

On September 30, 2008, Allscripts sold its Physicians Interactive business. The operating results of the Physicians Interactive business have been presented as discontinued operations in the accompanying unaudited consolidated statement of operations for all periods presented. The consolidated balance sheet as of December 31, 2007 includes the Physicians Interactive business and has not been presented as discontinued operations due to the amounts being insignificant.

2. Revenue Recognition

Revenue from software licensing arrangements, where the service element is considered essential to the functionality of the other elements of the arrangement, is accounted for under American Institute of Certified Public Accountants Statement of Position ("SOP") 81-1, "Accounting for Performance of Construction-Type Contracts and Certain Production-Type Contracts." Allscripts recognizes revenue on an input basis using actual hours worked as a percentage of total expected hours required by the arrangement, provided that the fee is fixed and determinable and collection of the receivable is probable. Maintenance and support from these agreements is recognized over the term of the support agreement based on vendor-specific objective evidence of fair value of the maintenance revenue, which is generally based upon contractual renewal rates. For agreements that are deemed to have extended payment terms, revenue is recognized using the input method but is limited to the amounts due and payable.

Revenue from software licensing arrangements where the service element is not considered essential to the functionality of the other elements of the arrangement is accounted for under SOP 97-2, "Software Revenue Recognition," as amended by SOP 98-9, "Modification of SOP 97-2, Software Revenue Recognition, With Respect to Certain Transactions." Such revenue is recognized upon shipment of the software or as services are performed, provided persuasive evidence of an arrangement exists, fees are considered fixed and determinable, and collection of the receivable is considered probable. The revenue recognized for each separate element of a multiple-element software contract is based upon vendor-specific objective evidence of fair value, which is based upon the price the customer is required to pay when the element is sold separately.

Revenue from certain value-added reseller ("VAR") relationships in which software is directly sold to VARs is recognized upon delivery of the software in accordance with SOP 97-2 assuming all other revenue recognition criteria have been met. In certain instances, the ultimate end-user customers of the VARs will separately contract with Allscripts to perform implementation services relating to the software purchased. Under the provisions of SOP 97-2 these two independent transactions are accounted for separately with the software sold to the VARs being recognized upon software delivery and the implementation services contracted separately with the end-user VAR customers being recognized as the work is performed.

Revenue from the prepackaged medications segment, from the sale of medications, net of provisions for estimated returns, is recognized upon shipment of the pharmaceutical products, the point at which the customer takes ownership and assumes risk of loss, when no performance obligations remain and collection of the receivable is probable. Allscripts offers the right of return on pharmaceutical products under various policies and estimates and maintains reserves for product returns based on historical experience following the provisions of FAS No. 48, "Revenue Recognition When Right of Return Exists."

Certain of our customer arrangements encompass multiple deliverables. We account for these arrangements in accordance with Emerging Issues Task Force ("EITF") No. 00-21, "Accounting for Revenue Arrangements with Multiple Deliverables" ("EITF 00-21"). If the deliverables meet the separation criteria in EITF 00-21, the deliverables are separated into separate units of accounting, and revenue is allocated to the deliverables based on their relative fair values. The criteria specified in EITF 00-21 are that the delivered item has value to the customer on a stand-alone basis, there is objective and reliable evidence of the fair value of the undelivered item, and if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. Applicable revenue recognition criteria is considered separately for each separate unit of accounting.

Management applies judgment to ensure appropriate application of EITF 00-21, including value allocation among multiple deliverables, determination of whether undelivered elements are essential to the functionality of delivered elements and timing of

[Table of Contents](#)

revenue recognition, among others. For those arrangements where the deliverables do not qualify as a separate unit of accounting, revenue from all deliverables is treated as one accounting unit and recognized on a straight-line basis over the term of the arrangement. Changes in circumstances and customer data may affect management's analysis of EITF 00-21 criteria, which may cause Allscripts to adjust upward or downward the amount of revenue recognized under the arrangement.

In accordance with EITF issued Consensus 01-14, "Income Statement Characterization of Reimbursements for 'Out-of-Pocket' Expenses Incurred," revenue includes reimbursable expenses charged to our clients.

In June 2006, the Financial Accounting Standards Board ("FASB") ratified the consensus reached on EITF No. 06-3 ("EITF 06-3", "How Taxes Collected from Customers and Remitted to Governmental Authorities Should be Presented in the Income Statement (That is, Gross versus Net Presentation).") Allscripts presents any tax assessed by a governmental authority that is directly imposed on a revenue-producing transaction between a seller and a customer on a net basis. We did not modify our accounting policy in connection with the adoption of EITF 06-3, and therefore the adoption of this EITF did not have an impact on our consolidated results of operations or financial condition.

As of September 30, 2008 and December 31, 2007, there was \$20,553 and \$18,400, respectively, of revenue earned on contracts in excess of billings, which are included in the balance of accounts receivable. Billings on contracts where revenue has been earned in excess of billings are expected to occur according to the contract terms. Deferred revenue consisted of the following:

	September 30, 2008	December 31, 2007
Prepayments and billings in excess of revenue earned on contracts in progress for software and services provided by Allscripts and included in the software and related services segment	\$24,359	\$25,669
Prepayments and billings in excess of revenue earned on contracts in progress for support and maintenance provided by Allscripts and included in the software and related services segment	29,966	15,623
Prepayments and billings in excess of revenue earned for interactive physician education sessions and related services provided by the Allscripts' physicians' interactive business unit and included in the information services segment	—	4,648
Total deferred revenue	<u>\$54,325</u>	<u>\$45,940</u>

3. Business Combinations

Misys Healthcare Systems, LLC

On March 17, 2008, Allscripts entered into an Agreement and Plan of Merger (the "Merger Agreement") with Misys plc ("Misys"), a public limited company incorporated under the laws of England and Wales, Misys Healthcare Systems, LLC ("MHS"), a North Carolina limited liability company and wholly-owned indirect subsidiary of Misys and Patriot Merger Company, LLC, a North Carolina limited liability company and wholly-owned subsidiary of Allscripts ("Patriot").

On October 10, 2008, Allscripts completed the transactions contemplated by the Merger Agreement, which consisted of (i) the cash payment by an affiliate of Misys of approximately \$330,000 ("the Share Purchase") and (ii) the merger of Patriot with and into MHS, with MHS being the surviving company (the "Merger" and together with the Share Purchase, the "Transactions"). As a result of the Transactions, Misys, through its subsidiaries, owns approximately 82,886 shares of Allscripts common stock, or approximately 56.8% of the number of outstanding shares of Allscripts common stock. Pursuant to the Merger Agreement, Allscripts declared and paid a special cash dividend of \$330,000 or \$5.23 per share in connection with the closing of the Transactions.

Extended Care Information Network, Inc.

On December 31, 2007, Allscripts completed its acquisition of Extended Care Information Network, Inc. ("ECIN"), for a total of \$93,975 (which includes repayment of ECIN's indebtedness and transaction expenses). ECIN is a provider of hospital care management and discharge planning solutions. In connection with the ECIN acquisition, Allscripts created a new hospital solutions group designed to provide products and services under one umbrella, combining ECIN with Allscripts' existing emergency department information systems and its care management solution, Canopy.

The ECIN acquisition has been accounted for as a business combination under Statement of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations." The assets acquired and liabilities assumed have been recorded at the date of acquisition at their respective fair values.

[Table of Contents](#)

The results of operations of ECIN are included in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2008. The total purchase price for the acquisition, subject to finalization of the working capital adjustment as defined in the merger agreement, is \$93,975 and is broken down as follows:

Cash paid for acquisition of ECIN (includes consideration to shareholders, payment of ECIN indebtedness and certain ECIN transaction costs)	\$90,000
Preliminary net working capital payment	3,482
Acquisition-related transaction costs	493
Total preliminary purchase price	<u>\$93,975</u>

The above purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed based on management's estimates of their current fair values. Acquisition-related transaction costs include investment banking fees, loan commitment fees, legal and accounting fees and other external costs directly related to the ECIN acquisition.

The purchase price has been allocated as follows:

Acquired cash	\$5,723
Accounts receivable, net	3,065
Prepays and other current assets	667
Fixed assets and other long-term assets	3,876
Goodwill	63,787
Intangible assets	31,170
Deferred tax liability, net	(9,746)
Accounts payable and accrued liabilities	(1,989)
Deferred revenue	(2,261)
Other liabilities	(317)
Net assets acquired	<u>\$93,975</u>

Goodwill was determined based on the residual difference between the purchase cost and the value assigned to tangible and intangible assets and liabilities, and is not deductible for tax purposes. Among the factors that contributed to a purchase price resulting in the recognition of goodwill were ECIN's history of profitability and high operating margins, strong sales force and overall employee base, and leadership position in the healthcare information technology market. We have allocated \$63,787 to goodwill and \$31,170 to intangible assets. Of the \$31,170 intangible assets acquired, \$11,620 was assigned to developed technology rights with a useful life of 7 years, \$750 was assigned to trade names with a useful life of 18 months, \$11,680 was assigned to customer relationships with hospitals with a useful life of 20 years, \$4,370 was assigned to customer relationships with extended care facilities with a useful life of 15 years and \$2,750 was assigned to ECIN's sales backlog with a useful life of 54 months.

[Table of Contents](#)

The following unaudited pro forma information for Allscripts assumes the ECIN acquisition occurred on January 1, 2007. The unaudited pro forma supplemental results have been prepared based on estimates and assumptions, which we believe are reasonable and are not necessarily indicative of the consolidated financial position or results of income had the ECIN acquisition occurred on January 1, 2007, nor of future results of operations. The unaudited pro forma results for the three and nine months ended September 30, 2008 and 2007 are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Total revenue	\$81,804	\$74,487	\$227,689	\$209,837
Net income	\$4,016	\$3,632	\$6,448	\$12,838
Earnings per share:				
Basic	\$0.07	\$0.06	\$0.11	\$0.23
Diluted	\$0.07	\$0.06	\$0.11	\$0.22

The unaudited pro forma information for the three and nine months ended September 30, 2007 include the following adjustments:

- Increase to amortization expense of \$547 and \$1,642 for the three and nine months ended September 30, 2007 related to management's estimate of the fair value of intangible assets acquired as a result of the ECIN acquisition.
- Decrease to interest income of \$266 and \$798 for the three and nine months ended September 30, 2007 as a result of lower cash, cash equivalents and marketable securities balances assuming the acquisition of ECIN occurred on January 1, 2007.
- Increase to interest expense of \$380 and \$1,139 for the three and nine months ended September 30, 2007 as a result of assuming the \$50,000 of long-term debt incurred in connection with the ECIN acquisition was effective on January 1, 2007. This increase in interest expense is offset by a decrease in interest expense of \$129 and \$365 for the three and nine months ended September 30, 2007 due to Allscripts paying the balance of ECIN's long-term debt in connection with the ECIN acquisition.
- A decrease in revenue of \$252 and \$765 for the three and nine months ended September 30, 2007 relating to the timing of deferred revenue purchase accounting adjustments.
- The pro forma information includes a tax provision of \$480 and \$1,254 for the three and nine months ended September 30, 2007 to reflect a 40% tax provision.

Source Medical Solutions, Inc.

On July 10, 2007, Allscripts entered into an asset purchase agreement to acquire a certain number of practice management customer contracts from SourceMedical Solutions, Inc. for approximately \$11,685. SourceMedical provides comprehensive outpatient information solutions and services for more than 3,500 ambulatory surgery centers, rehabilitation clinics and diagnostic imaging centers nationwide.

The purchase price of \$11,685 has been recorded as of September 30, 2008 and has been allocated to the tangible and intangible assets acquired and liabilities assumed based on management's best estimates of the current fair values. A total of approximately \$2,429 has been allocated to goodwill and \$8,846 has been allocated to intangible assets with the remaining value attributed to tangible assets. Of the \$8,846 intangible assets acquired, \$7,280 was assigned to customer relationships with a useful life of 20 years, \$1,260 was allocated to developed technology rights with an estimated useful life of 8 years and \$306 was assigned to transition services with a useful life of 1 year. The results of operations of SourceMedical have been included in the accompanying consolidated statements of operations from the date of the SourceMedical acquisition. The Source Medical acquisition has been accounted for as a business combination under Statement of Financial Accounting Standards ("SFAS") No. 141, "Business Combinations." The assets acquired and liabilities assumed have been recorded at the date of acquisition at their respective fair values.

A4 Health Systems, Inc

During the nine months ended September 30, 2008, Allscripts made an immaterial adjustment to the goodwill recorded for the A4 acquisition. Allscripts originally recorded a deferred tax asset for excess tax benefits relating to stock options exercised totaling approximately \$9,500. This deferred tax asset was realized during the first quarter of 2006 when the deferred tax asset valuation allowance was reversed to goodwill in purchase accounting for the A4 acquisition. The deferred tax asset relating to the excess tax benefits for stock option exercises should be recorded at the time that Allscripts is able to reduce its income taxes payable for the benefit but based on its current net operating loss carry-forward position was not able to reduce income taxes payable. As a result, a decrease in deferred tax assets totaling approximately \$9,500 with a corresponding offset to goodwill was recorded during the nine months ended September 30, 2008.

[Table of Contents](#)

4. Discontinued Operations

On September 17, 2008, Allscripts entered into an Asset Purchase Agreement (the "PI Agreement") with Perseus Acquisition, Inc. ("Perseus"), pursuant to which Allscripts agreed to sell to Perseus the assets comprising Allscripts' information services segment which consisted solely of the Physicians Interactive business. The Physicians Interactive business provides clinical education and information solutions for physicians and patients. The purchase price for the Physicians Interactive business was \$11,500 in cash. The closing of the sale of the Physicians Interactive business occurred on September 30, 2008.

The results of the Physicians Interactive discontinued operations for the three and nine months ended September 30, 2008 and 2007 are included below in accordance with FAS 144:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Total revenue	\$3,918	\$3,555	\$11,634	\$11,529
Total cost of revenue	2,291	2,408	7,354	7,099
Gross Profit	1,627	1,147	4,280	4,430
Selling, general and administrative expenses	1,203	1,195	3,303	3,424
Net income (loss) from discontinued operations before tax	424	(48)	977	1,006
Provision for income taxes	165	(20)	381	402
Net income (loss) from discontinued operations	\$259	(\$28)	\$596	\$604
Gain on the sale of discontinued operations	\$3,253	\$—	\$3,253	\$—
Tax on gain on the sale of discontinued operations	1,268	—	1,268	—
Gain on the sale of discontinued operations, net of tax	\$1,985	\$—	\$1,985	\$—
Net income (loss) from discontinued operations	\$2,244	(\$28)	\$2,581	\$604

The current and non-current assets and liabilities of discontinued operations as of September 30, 2008 and December 31, 2007 are included below in accordance with FAS 144. The assets and liabilities as of September 30, 2008 are excluded from the consolidated balance sheet due to the Physicians Interactive sale closing on September 30, 2008. The Allscripts consolidated balance sheet as of December 31, 2007 includes the Physicians Interactive business and it has not been presented as discontinued operations due to the amounts being insignificant.

	September 30, 2008	December 31, 2007
Current assets of discontinued operations:		
Accounts receivable, net	\$5,009	\$3,162
Prepaid assets and other assets	626	858
Non-current assets of discontinued operations:		
Net fixed assets	774	142
Goodwill and intangibles	2,923	2,958
Capitalized software	2,581	3,714
Total assets	\$11,913	\$10,834
Current liabilities of discontinued operations:		
Accounts payable	\$272	\$1,039
Other accrued expenses	368	421
Deferred revenue	3,423	4,647
Total liabilities	\$4,063	\$6,107
Total net assets	\$7,850	\$4,727

5. Stock-Based Compensation

Impact of the Adoption of SFAS 123(R)

Allscripts elected to adopt the modified prospective application transition method as permitted by SFAS 123(R). Accordingly, during the three and nine months ended September 30, 2008 and 2007, Allscripts recorded stock-based compensation cost in accordance with SFAS 123(R) as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Stock-based compensation:				
Restricted stock	\$1,674	\$1,445	\$5,233	\$2,609
Stock options	5	64	18	181
Total stock-based compensation	\$1,679	\$1,509	\$5,251	\$2,790
Effect on net income, net of tax	\$1,024	\$905	\$3,203	\$1,674
Effect on net income per share:				
Basic	\$0.02	\$0.02	\$0.06	\$0.03
Diluted	\$0.02	\$0.01	\$0.06	\$0.03

[Table of Contents](#)

Stock Options

SFAS 123(R) requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. As of September 30, 2008 and December 31, 2007, the unrecorded deferred stock-based compensation balance related to stock options was \$22 and \$39, respectively, after estimated forfeitures. Allscripts did not grant any stock options during the nine months ended September 30, 2008 or 2007.

The following table summarizes the combined activity with respect to stock options granted under Allscripts' equity incentive plans during the periods indicated:

	<u>Options Outstanding</u>	<u>Weighted- Average Exercise Price</u>	<u>Options Exercisable</u>	<u>Weighted- Average Exercise Price</u>
Balance at December 31, 2006	5,532	\$7.81	5,485	\$7.80
Options exercised	(1,915)	\$4.85		
Options forfeited	(62)	\$29.00		
Balance at December 31, 2007	3,555	\$9.02	3,550	\$9.02
Options exercised	(380)	\$3.93		
Options forfeited	(43)	\$21.87		
Balance at September 30, 2008	<u>3,132</u>	\$9.41	3,129	\$9.40

The aggregate intrinsic value of stock options outstanding as of September 30, 2008 was \$16,692, which is based on Allscripts' closing stock price of \$12.44 as of September 30, 2008. The intrinsic value of stock options outstanding represents the amount that would have been received by the option holders had all option holders exercised their stock options as of that date. The total number of vested and exercisable stock options as of September 30, 2008 was 3,129, with an intrinsic value of \$16,692.

The total intrinsic value of stock options exercised during the nine months ended September 30, 2008 was \$2,024. The total cash received from employees as a result of employee stock option exercises during the nine months ended September 30, 2008 was \$1,494, net of related taxes. Allscripts settles employee stock option exercises with newly issued common shares.

Restricted Stock Awards and Units

During the nine months ended September 30, 2008, management awarded 848 shares of restricted stock units to certain employees under the Amended and Restated 1993 Stock Incentive Plan, with a weighted average fair value of \$12.69 per share. The awards of restricted stock have an average four-year vesting term. Upon termination of an employee's employment with Allscripts, any unvested shares of restricted stock will be forfeited. As of September 30, 2008 and December 31, 2007, 2,114 and 1,266 restricted stock awards and units combined had been awarded, respectively, of which 1,355 and 937 were unvested. The fair value of the shares of unvested restricted stock on the date of the grant is amortized ratably over the vesting period. As of September 30, 2008 and December 31, 2007, \$16,148 and \$13,720, respectively, of unearned compensation related to unvested awards of restricted stock was netted against the balance of additional paid in capital and will be recognized over the remaining vesting terms of the awards.

Our Chief Operating Officer, Benjamin E. Bulkley, terminated his employment with Allscripts effective September 19, 2008. In connection with Mr. Bulkley's termination, the Company settled the 83 restricted stock units that were expected to vest upon termination with a cash payment.

Pursuant to restricted stock award agreements, the unvested restricted shares will vest upon the occurrence of a Change of Control, as defined. This Change of Control provision was triggered upon consummation of the Misys transaction on October 10, 2008 for all shares granted prior to the announcement of such transaction in March 2008.

[Table of Contents](#)

The following table summarizes the status of unvested restricted stock outstanding at September 30, 2008 and changes during the nine months then ended:

	Shares	Weighted Average Grant Date Fair Value
Unvested restricted stock at December 31, 2006	666	\$18.18
Awarded	525	\$24.87
Vested	(158)	\$18.23
Forfeited	(92)	\$20.78
Unvested restricted stock at December 31, 2007	941	\$21.65
Awarded	848	\$12.69
Vested	(274)	\$21.41
Forfeited	(154)	\$20.28
Unvested restricted stock at September 30, 2008	1,361	\$16.27

A total of 967 restricted stock awards vested subsequent to September 30, 2008 as a result of the Change of Control provision triggered by the Misys transaction that was consummated on October 10, 2008. A total of 394 restricted stock awards did not vest in connection with the Misys transaction and remain outstanding.

Employee Stock Purchase Plan

The Employee Stock Purchase Plan (“ESPP”) became effective on July 1, 2006 and allows eligible employees to authorize payroll deductions of up to 20% of their base salary to be applied toward the purchase of full shares of common stock on the last day of the offering period. Offering periods under the ESPP are three months in duration and begin on each January 1, April 1, July 1, and October 1. Shares will be purchased on the last day of each offering period at a price of 95% of fair market value of the common stock on such date as reported on Nasdaq. The aggregate number of shares of Allscripts common stock that may be issued under the ESPP may not exceed 250 shares and no one employee may purchase any shares under the ESPP having a collective fair market value greater than \$25 in any one calendar year. The shares available for purchase under the ESPP may be drawn from either authorized but previously unissued shares of common stock or from reacquired shares of common stock, including shares purchased by Allscripts in the open market and held as treasury shares.

Allscripts treats the ESPP as a non-compensatory plan in accordance with SFAS No. 123(R). During the nine months ended September 30, 2008 and 2007, 51 and 26 shares were issued under the ESPP which resulted in \$569 and \$665 in net proceeds, respectively.

6. Cash, Cash Equivalents and Marketable Securities

Cash and cash equivalent balances at September 30, 2008 and December 31, 2007 consist of cash and money market funds with original maturities at the time of purchase of less than 90 days. Allscripts’ cash, cash equivalents, short-term marketable securities and long-term marketable securities are invested in overnight repurchase agreements, money market funds, U.S. and non-U.S. government debt securities, and corporate debt securities. The carrying values of cash and cash equivalents, short-term marketable securities and long-term marketable securities held by Allscripts are as follows:

	September 30, 2008	December 31, 2007
Cash and cash equivalents:		
Cash	\$59,101	\$43,017
Money market funds	12,088	768
	71,189	43,785
Short-term marketable securities:		
Corporate debt securities	5,435	5,759
	5,435	5,759
Long-term marketable securities:		
U.S. government and agency debt obligations	1,923	2,724
Corporate debt securities	922	10,735
	2,845	13,459
Total cash, cash equivalents and marketable securities	\$79,469	\$63,003

In September 2006, the Financial Accounting Standards Board (“FASB”) issued SFAS 157, *Fair Value Measurements* (“FAS 157”). FAS 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007. Under FAS 157, assets and liabilities are required to be recorded at fair value in the financial statements. The fair values are categorized based upon the level of judgment associated with the inputs used to measure their value. Hierarchical levels, as defined in SFAS No. 157, are as follows:

Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date.

[Table of Contents](#)

Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability.

Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.

We adopted FAS 157 as required at the beginning of our fiscal year 2008 and the adoption did not have a material effect on our consolidated financial statements. All assets and liabilities that are required to be measured under FAS 157 are measured using Level 1 inputs.

7. Comprehensive Income

Comprehensive income includes all changes in stockholders' equity during a period except those resulting from investments by owners and distributions to owners.

The components of comprehensive income are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net income	\$4,016	\$4,124	\$6,448	\$14,619
Other comprehensive income:				
Unrealized gain (loss) on marketable securities, net of tax	(60)	11	(170)	74
Comprehensive income	<u>\$3,956</u>	<u>\$4,135</u>	<u>\$6,278</u>	<u>\$14,693</u>

The components of accumulated other comprehensive income (loss), net of income tax, consist of unrealized losses on Allscripts marketable securities. The components of the net unrealized loss on marketable securities, net of tax, are as follows:

	September 30, 2008	December 31, 2007
Short-term marketable securities:		
Gross unrealized gains	\$70	\$—
Gross unrealized losses	(114)	(1)
Net short-term unrealized losses	(44)	(1)
Long-term marketable securities:		
Gross unrealized gains	111	9
Gross unrealized losses	(326)	(97)
Net long-term unrealized losses	(215)	(88)
Total net unrealized losses on marketable securities	<u>(\$259)</u>	<u>(\$89)</u>

8. Net Income Per Share

Allscripts accounts for net income per share in accordance with FAS No. 128, "Earnings per Share" ("FAS 128"). FAS 128 requires the presentation of "basic" income per share and "diluted" income per share. Basic income per share is computed by dividing the net income by the weighted-average shares of outstanding common stock. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive potential common stock equivalents. Dilutive common stock equivalent shares consist primarily of stock options, restricted stock awards and conversion of the Senior Convertible Debentures.

[Table of Contents](#)

The components of net earnings available for diluted per-share calculation and diluted weighted average common shares outstanding are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Net earnings available for diluted per-share calculation:				
Net income	\$4,016	\$4,124	\$6,448	\$14,619
Interest expense on 3.5% Senior Convertible Notes, net of tax	—	521	—	1,563
Net earnings available for diluted per-share calculation	<u>\$4,016</u>	<u>\$4,645</u>	<u>\$6,448</u>	<u>\$16,182</u>
	Three Months Ended September 30,		Nine Months Ended September 30,	
	2008	2007	2008	2007
Weighted average shares outstanding:				
Basic weighted average common shares	57,008	56,191	56,763	55,500
Dilutive effect of options and restricted stock awards	1,193	1,705	1,021	1,712
Dilutive effect of 3.50% Senior Convertible Debentures	—	7,329	—	7,329
Diluted weighted average common shares	<u>58,201</u>	<u>65,225</u>	<u>57,784</u>	<u>64,541</u>

Under the provisions of EITF 04-8, the as-if converted 7,329 shares and interest expense related to Allscripts' 3.5% Senior Convertible Debentures due 2024 were excluded from the three and nine months ended September 30, 2008 as the effects were anti-dilutive.

9. Investment in Promissory Note Receivable and Minority Interest

On August 18, 2004, Allscripts entered into a Convertible Secured Promissory Note Purchase Agreement ("Note Purchase Agreement") with Medem and certain other investors. Under the Note Purchase Agreement, Allscripts acquired a convertible secured promissory note in the aggregate principal amount of \$2,600 ("Promissory Note") under which Medem borrowed \$2,600 from Allscripts. On May 28, 2007, Allscripts converted the Promissory Note into 2,317 shares of Medem's Series A Common Stock.

In connection with the Note Purchase Agreement described above, Allscripts also entered into a Share Purchase Agreement pursuant to which Allscripts purchased shares of Medem's Series A Common Stock, shares of Medem's Series B Common Stock, and a three-year option to acquire an additional interest in Medem, all for an aggregate purchase price equal to \$500 in cash (the "Share Purchase Agreement"). Pursuant to such three-year option in the Share Purchase Agreement Allscripts had the right to purchase an additional (i) 118 shares of Series A Common Stock, par value of \$0.001 per share, of Medem, and (ii) 1,061 shares of Series B Common Stock, par value of \$0.001 per share, of Medem for an exercise price of \$600.

On May 28, 2007, Allscripts entered into an Option Purchase Agreement (the "Option Agreement") with Medem. Pursuant to the Option Agreement, Allscripts sold to Medem the irrevocable three-year option held by Allscripts for a total purchase price of \$2,592. The fair value of the three-year option was estimated at approximately \$200 at the time of investment on August 18, 2004 and the sale of the option resulted in a gain of approximately \$2,392.

As of September 30, 2008, Allscripts owns 2,338 shares, or 18.7%, of Medem's Series A Voting Common Stock and 91 shares, or 4.6%, of Medem's Series B Common Stock (combined 16.8% equity ownership). Allscripts' total investment in Medem is \$2,900 under the cost basis of accounting as of September 30, 2008 and December 31, 2007 and is recorded in other assets on the consolidated balance sheets.

10. Long-Term Debt and Bank Credit Facility

Senior Convertible Debentures

In July 2004, Allscripts completed a private placement of \$82,500 of 3.50% Senior Convertible Debentures due 2024 ("Notes"). The Notes can be converted, in certain circumstances, into approximately 7,300 shares of common stock based upon a conversion price of approximately \$11.26 per share, subject to adjustment for certain events.

The Notes are only convertible under certain circumstances, including: (i) during any fiscal quarter if the closing price of Allscripts' common stock for at least 20 trading days in the 30 trading-day period ending on the last trading day of the preceding fiscal quarter exceeds \$14.64 per share; (ii) if Allscripts calls the Notes for redemption; or (iii) upon the occurrence of certain specified corporate transactions, as defined. Allscripts has the right to deliver common stock, cash or a combination of cash and

[Table of Contents](#)

shares of common stock. The Notes were convertible during the quarter ended September 30, 2007 by virtue of the last reported sale price for Allscripts' common stock having exceeded \$14.64 for twenty consecutive days in the 30 trading-day period ending on each fiscal quarter end date but were not convertible based on the trading price conversion trigger during the quarter ended September 30, 2008. No notes were converted as of September 30, 2008 or September 30, 2007. However, in connection with the Transactions, holders of \$54,632 aggregate principal amount of the Notes exercised their right to convert into Allscripts common stock. As a result of this conversion, Allscripts principal balance on the 3.5% Senior Convertible Notes was reduced by \$54,632 to \$27,868 on October 10, 2008. The timing of our obligation on the Notes may change as it relates to funding interest payments and making a principal payment on the Notes based on whether the holders elect to convert the Notes. Upon conversion, Allscripts may redeem some or all of the Notes for cash any time on or after July 20, 2009 at the Notes' full principal amount plus accrued and unpaid interest, if any. Holders of the Notes may require Allscripts to repurchase some or all of the Notes on July 15, 2009, 2014 and 2019 or, subject to certain exceptions, upon a change of control of Allscripts.

Credit Facility

On December 31, 2007, Allscripts and its subsidiaries entered into a new credit agreement (the "Original Credit Facility") with JPMorgan Chase Bank, N.A., as sole administrative agent, which provides for a total unsecured commitment of \$60,000 and matures on January 1, 2012. On August 15, 2008, Allscripts and its subsidiaries entered into an Amended and Restated Credit Agreement (the "Credit Facility") with JPMorgan Chase Bank, N.A., as the sole administrative agent. The Credit Facility amends and restates the Original Credit Facility. The Credit Facility provides for a total unsecured commitment of \$75,000, an increase of \$15,000 from the Original Credit Facility, and matures on August 15, 2012. The Credit Facility is available in the form of letters of credit and revolving loans.

As of September 30, 2008 and December 31, 2007, \$50,000 in borrowings were outstanding and \$0 in letters of credit were outstanding under the Credit Facility. The proceeds received by Allscripts under the Credit Facility were used to partially finance the acquisition of ECIN described in Note 3. The Credit Facility, including, if drawn, the Backstop (as defined below), will initially bear interest at LIBOR plus 1.625% and thereafter will be based upon the Company's leverage ratio as of the last day of the most recently ended fiscal quarter or fiscal year, commencing with the date of delivery of the Company's financial statements for the fiscal quarter ending after the Closing Date, pursuant to the terms of the Credit Facility.

The Credit Facility also provides a backstop facility of up to \$50,000 (the "Backstop") to be used to fund any repurchases of Allscripts' 3.50% Convertible Senior Debentures arising by reason of the Transactions. Allscripts launched its repurchase offer for the Debentures on November 7, 2008. The Backstop, if drawn upon, will amortize in equal quarterly installments and mature on the second anniversary of such draw. The Credit Facility's lenders' obligation to provide the Backstop terminates upon the earliest to occur of: (i) the Business Day immediately following the Change of Control Repurchase Date and (ii) the date that is one-hundred and twenty (120) days after the date on which the Transactions are consummated. There is no amount outstanding under the Backstop and no default under the Credit Facility as of September 30, 2008. The Credit Facility contains customary representations, warranties, covenants and events of default. The Credit Facility also contains certain financial covenants, including but not limited to, leverage and coverage ratios to be calculated on a quarterly basis.

Allscripts received approximately \$49,397 in net proceeds under the Credit Facility after deduction for debt issuance costs. The debt costs of \$603 have been capitalized as other assets and are being amortized as interest expense over four years using the effective interest method.

Promissory Note

In connection with the acquisition of A4, Allscripts assumed a secured promissory note with an aggregate principal amount of \$3,400 as of March 2, 2006, maturing on October 31, 2015. The promissory note bears interest at 7.85% per annum, and principal and interest are due monthly. In the event of prepayment in full or in part, Allscripts will be subject to a prepayment fee of 1% or more, as described in the related promissory note agreement, of the amount of principal prepaid on the promissory note. The promissory note is secured by the former corporate facilities of A4 and any lease or rental payments as defined in the related agreements. On August 20, 2008, Allscripts entered into an agreement to sell the former corporate facilities of A4 (see Note 13). The secured promissory note will be paid in full upon closing of the sale which is expected to occur in November 2008.

Long-term debt outstanding as of September 30, 2008 and December 31, 2007 consists of the following:

	September 30, 2008	December 31, 2007
3.5% Senior convertible debt	\$82,500	\$82,500
Long-term revolving Credit Facility, LIBOR plus 0.80% interest	50,000	50,000
7.85% Secured promissory note	2,734	2,941
Total debt	135,234	135,441
Less: Current portion of long-term debt	296	279
Total long-term debt, net of current portion	\$134,938	\$135,162

Interest expense for the three months ended September 30, 2008 and 2007 was \$1,389 and \$781, respectively, and \$171 and \$146 in debt issuance cost amortization, respectively. Interest expense for the nine months ended September 30, 2008 and 2007 was \$4,119 and \$2,347, respectively, and \$468 and \$443 in debt issuance cost amortization, respectively.

11. Income Taxes

Allscripts adopted FASB Interpretation No. 48 (“FIN 48”), Accounting for Uncertainty in Income Taxes, on January 1, 2007. As a result of the implementation of FIN 48, we recorded an approximate \$273 increase in the liability for unrecognized tax benefits, which was accounted for as an increase to the January 1, 2007 balance of goodwill in relation to the A4 acquisition on March 2, 2006. As of January 1, 2007, the gross amount of unrecognized tax benefits was \$6,400 of which \$6,400 was recorded as a reduction to certain tax carryovers. The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate is \$4,600. All remaining amounts would be adjustments to goodwill.

Allscripts recognized accrued interest and penalties related to unrecognized tax benefits in income tax expense and has also accrued amounts as adjustments to goodwill. It is unlikely that the balance of the unrecognized tax benefits will change in any material amount in the next 12 months.

Allscripts and its subsidiaries file income tax returns in the U.S. federal jurisdiction and with various state jurisdictions. Tax years 1993 and forward remain open for examination for federal tax purposes. To the extent utilized in future years’ tax returns, net operating loss carryforwards at September 30, 2008 will remain subject to examination until the respective tax year is closed. The statute is similarly open for state income tax purposes.

12. Business Segments

FAS No. 131, “Disclosures about Segments of a Business Enterprise and Related Information,” establishes standards for reporting information about operating segments in annual financial statements and requires selected information about operating segments in interim financial reports issued to stockholders. Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance.

Allscripts currently organizes its business around groups of similar products, which results in two reportable segments: software and related services and prepackaged medications. As a result of the sale of our Physicians Interactive business to Perseus Acquisition, Inc. on September 30, 2008, the results of the previously disclosed information services segment are included in discontinued operations (see Note 4) and the information services business is no longer included as a reportable segment of the Company.

The software and related services segment derives its revenue from the sale and installation of clinical software that provides point-of-care decision support solutions, document imaging solutions, and the resale of related hardware. The prepackaged medications segment derives its revenue from the repackaging, sale, and distribution of medications and medical supplies. Allscripts does not report its assets by segment. Allscripts does not allocate interest income, interest expense, other income or income taxes to its operating segments. In addition, Allscripts records corporate selling, general, and administration expenses, amortization of intangibles, restructuring and other related charges in its unallocated corporate costs. These costs are not included in the evaluation of the financial performance of Allscripts’ operating segments.

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2008	2007	2008	2007
Revenue:				
Software and related services	\$71,813	\$58,985	\$198,610	\$164,906
Prepackaged medications	9,991	10,904	29,079	32,072
Total revenue	<u>\$81,804</u>	<u>\$69,889</u>	<u>\$227,689</u>	<u>\$196,978</u>
Income from operations:				
Software and related services	\$21,492	\$16,997	\$56,066	\$50,636
Prepackaged medications	847	762	2,988	2,941
Unallocated corporate	(18,012)	(10,844)	(49,210)	(32,924)
Income from continuing operations	4,327	6,915	9,844	20,653
Interest income, interest expense, and other income (expense), net	(1,432)	7	(3,517)	287
Gain on sale of equity investment	—	—	—	2,392
Income from continuing operations before income taxes	<u>\$2,895</u>	<u>\$6,922</u>	<u>\$6,327</u>	<u>\$23,332</u>

13. Subsequent Event

Merger with Misys Healthcare Systems, Inc.

On March 17, 2008, Allscripts entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Misys plc (“Misys”), a public limited company incorporated under the laws of England and Wales, Misys Healthcare Systems, LLC (“MHS”), a North Carolina limited liability company and wholly-owned indirect subsidiary of Misys and Patriot Merger Company, LLC, a North Carolina limited liability company and wholly-owned subsidiary of Allscripts (“Patriot”).

[Table of Contents](#)

On October 10, 2008, Allscripts completed the transactions contemplated by the Merger Agreement, which consisted of (i) the cash payment by an affiliate of Misys of approximately \$330,000 (the "Share Purchase") and (ii) the merger of Patriot with and into MHS, with MHS being the surviving company (the "Merger" and together with the Share Purchase, the "Transactions"). As a result of the Transactions, Misys, through its subsidiaries, owns approximately 82,886 shares of Allscripts common stock, or approximately 56.8% of the number of outstanding shares of Allscripts common stock. Pursuant to the Merger Agreement, Allscripts declared and paid a special cash dividend of \$330,000 or \$5.23 per share in connection with the closing of the Transactions.

In connection with the closing of the Transactions, effective October 10, 2008, the fiscal year end of Allscripts-Misys was changed to May 31. Pursuant to the stock option and restricted stock award agreements, unvested stock options and restricted shares of Allscripts common stock vest upon the occurrence of a Change of Control, as defined. This Change of Control provision was triggered upon consummation of the Misys transaction on October 10, 2008 for all shares granted prior to the announcement of such transaction in March 2008.

Sale of Building

On August 20, 2008, A4 Realty, LLC ("A4"), a wholly-owned indirect subsidiary of Allscripts Healthcare Solutions, Inc. ("Allscripts"), entered into a Contract of Purchase and Sale (the "Sale Agreement") to sell its office building property located in the City of Cary, North Carolina (the "Cary Sale"). The purchase price for the Cary Sale is \$7,250. Pursuant to the Sale Agreement, buyer has a period of sixty (60) days to investigate and examine the property and may, for any reason during such examination period, terminate the Sale Agreement, a period which expired on October 19, 2008. The closing of the Cary Sale is expected to occur on November 18, 2008 and the secured promissory note (see Note 10) will be paid in full upon closing. A gain of approximately \$2,000 is expected to be realized upon the close of the transaction.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

Allscripts-Misys Healthcare Solutions, Inc. is a leading provider of clinical software, connectivity and information solutions that physicians use to improve the quality of healthcare. Our businesses provide innovative solutions that inform physicians with just right, just in time information, connect physicians to each other and to the entire community of care, and transform healthcare, improving both the quality and efficiency of care. We provide clinical software applications, including Electronic Health Record (EHR), practice management, electronic prescribing, Emergency Department Information System (EDIS), hospital care management and document imaging solutions through our clinical solutions businesses. Additionally, until the sale of our Physicians Interactive business on September 30, 2008, we provided clinical education and information solutions for physicians and patients through our physicians interactive business unit. We provide additional physician-patient connectivity solutions through our partnership with Medem. We also provide prepackaged medication fulfillment services through our medication services business unit.

We report our financial results utilizing two business segments: software and related services segment and prepackaged medications segment. The software and related services segment consists of clinical software solutions offered by our clinical solutions and hospital solutions businesses. Our award-winning EHR solutions are designed to enhance physician productivity using Tablet PCs, wireless handheld devices or desktop workstations for the purpose of automating the most common physician activities, including prescribing, dictating, ordering lab tests and viewing results, documenting clinical encounters and capturing charges, among others. Our Practice Management solutions combine scheduling and financial management tools in a single package with functionality including rules-based appointment scheduling, multi-resource and recurring appointment features, referral and eligibility indicators, and appointment and claims management.

TouchWorks EHR and TouchWorks PM, which are both offered individually and as a combined solution, have the functionality to handle the complexities of large physician practice groups with 25 or more physicians. For physician practice groups with fewer than 25 physicians that are seeking an EHR, a practice management system, or a combined EHR and practice management solution, we offer our HealthMatics EHR, Ntierprise Practice Management and HealthMatics Office, which combines the two offerings into one complete solution for clinical and back-office automation.

TouchScript is an e-prescribing solution that physicians can access via the Internet to quickly, safely and securely prescribe medications, check for drug interactions, access medication histories, review drug reference information, and send prescriptions directly to a pharmacy or mail order facility. TouchScript can be a starting point for medical groups to seamlessly transition over time to a complete EHR. Another e-prescribing offering, eRx NOW, is an easy-to-use, web-based solution that is safe, secure, requires no downloading and no new hardware. eRx NOW is accessible by Internet on computers, handheld devices and cell phones and is offered free of charge to every prescriber in America via the National ePrescribing Patient Safety Initiative, a collaborative initiative introduced and led by us to enhance patient safety and reduce preventable medication errors.

Our offerings for hospitals that are seeking EDIS and care management solutions include HealthMatics ED, EmSTAT and Canopy. HealthMatics ED electronically streamlines processes for large hospital Emergency Departments, including tracking, triage, nurse and physician charting, disposition and reporting. EmSTAT offers similar functionality for streamlining the Emergency Department care process in small hospitals. Canopy is a Web-based solution that streamlines and speeds the patient care management process by automating utilization, case, discharge and quality management processes relating to patient hospital visits. On December 31, 2007, we acquired Extended Care Information Network, Inc. ("ECIN"), a provider of hospital care management and discharge planning software. ECIN's web-based solutions include Utilization Management, Discharge Planning and Case Management systems that assist hospitals in streamlining case management workflow, increasing productivity, improving patient throughput and reducing length of stay.

Our prepackaged medications segment is comprised of our medication services business unit. This business unit provides point-of-care medication management and medical supply services and solutions for physicians and other healthcare providers.

As a result of the sale of our Physicians Interactive business on September 30, 2008, the results of the previously disclosed information services segment are included in discontinued operations (see Note 4 to the consolidated financial statements).

[Table of Contents](#)

The composition of our revenue by segment for the three-month periods ended on the dates indicated below is as follows:

	2008			2007			
	Sept. 30	June 30	March 31	Dec. 31	Sept. 30	June 30	March 31
Software and related services	\$71,813	\$68,179	\$58,618	\$57,767	\$58,985	\$54,681	\$51,240
Prepackaged medications	9,991	9,493	9,595	11,887	10,904	10,939	10,229
Total revenue	<u>\$81,804</u>	<u>\$77,672</u>	<u>\$68,213</u>	<u>\$69,654</u>	<u>\$69,889</u>	<u>\$65,620</u>	<u>\$61,469</u>

Cost of revenue for the software and related services segment consists primarily of salaries, bonuses and benefits of our billable professionals, third-party software costs, hardware costs, capitalized software amortization and other direct engagement costs. Cost of revenue for the prepackaged medications segment consists primarily of the cost of the medications, cost of salaries, bonuses and benefits for repackaging personnel, shipping costs, repackaging facility costs and other costs.

Selling, general and administrative expenses consist primarily of salaries, bonuses and benefits for management and support personnel, commissions, facilities costs, depreciation and amortization, general operating expenses, non-capitalizable product development expenses and selling and marketing expenses. Selling, general and administrative expenses for each segment consist of expenses directly related to that segment.

Merger Agreement

On March 17, 2008, Allscripts entered into an Agreement and Plan of Merger (the "Merger Agreement") with Misys plc ("Misys"), a public limited company incorporated under the laws of England and Wales, Misys Healthcare Systems, LLC ("MHS"), a North Carolina limited liability company and wholly-owned indirect subsidiary of Misys and Patriot Merger Company, LLC, a North Carolina limited liability company and wholly-owned subsidiary of Allscripts ("Patriot").

On October 10, 2008, Allscripts completed the transactions contemplated by the Merger Agreement, which consisted of (i) the cash payment by an affiliate of Misys of approximately \$330,000 ("the Share Purchase") and (ii) the merger of Patriot with and into MHS, with MHS being the surviving company (the "Merger" and together with the Share Purchase, the "Transactions"). As a result of the Transactions, Misys, through its subsidiaries, owns approximately 82,886 shares of Allscripts common stock, or approximately 56.8% of the number of outstanding shares of Allscripts common stock. Pursuant to the Merger Agreement, Allscripts declared and paid a special cash dividend of \$330,000 or \$5.23 per share in connection with the closing of the Transactions. At the closing of the Merger, Allscripts changed its name to Allscripts-Misys Healthcare Solutions, Inc.

Recent Accounting Pronouncements

In June 2008, the Financial Accounting Standards Board issued EITF No. 03-6-1, "*Determining Whether Instruments Granted in Share-Based Payment Transactions Are Participating Securities*" ("EITF 03-6-1"). EITF 03-6-1 states that unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents are "participating securities" as defined in EITF 03-6, "*Participating Securities and the Two-Class Method under FASB Statement No. 128*", and therefore should be included in computing earnings per share using the two-class method. According to EITF 03-6-1, a share-based payment award is a participating security when the award includes nonforfeitable rights to dividends or dividend equivalents. The EITF is effective for fiscal years beginning after December 15, 2008. The Company has not historically declared dividends and we do not intend to declare dividends in the future, therefore we do not expect EITF 03-6-1 to have an effect on our consolidated financial position or results of operations.

In June 2008, the Financial Accounting Standards Board issued EITF Issue No. 08-4, "*Transition Guidance for Conforming Changes to Issue No. 98-5*" ("EITF No. 08-4"). The objective of EITF No. 08-4 is to provide transition guidance for conforming changes made to EITF No. 98-5, "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios", that result from EITF No. 00-27 "Application of Issue No. 98-5 to Certain Convertible Instruments", and SFAS No. 150, "Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity". This Issue is effective for financial statements issued for fiscal years ending after December 15, 2008, with early application permitted. Management is currently evaluating the impact of adoption of EITF No. 08-4 on the accounting for the convertible debt.

[Table of Contents](#)

In May 2008, the Financial Accounting Standard Board issued FASB Staff Position (FSP) No. APB 14-1 *Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)* (“APB 14-1”). This FSP specifies that issuers of convertible debt instruments should separately account for the liability and equity components of the instrument in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. FSP APB 14-1 is effective for fiscal years beginning after December 15, 2008, does not grandfather existing instruments, will not permit early application and will require retrospective application to all periods presented. Management is currently in the process of quantifying the impact of the FSP on our consolidated financial position and results of operations.

In December 2007, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standards No. 141 (revised 2007), *Business Combinations* (“FAS 141R”). FAS 141R establishes principles and requirements for how the acquirer in a business combination recognizes and measures in its financial statements the fair value of identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at the acquisition date. FAS 141R determines what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. FAS No. 141R is effective for fiscal years beginning after December 15, 2008. We are currently evaluating the impact of adopting FAS 141R on our consolidated results of operations and financial condition and plan to adopt it as required in the first quarter of fiscal 2010.

In December 2007, the Financial Accounting Standards Board issued SFAS 160, *Noncontrolling Interests in Consolidated Financial Statements* (“FAS 160”), an amendment of Accounting Research Bulletin No. 51, *Consolidated Financial Statements* (“ARB 51”). FAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. Minority interests will be recharacterized as noncontrolling interests and will be reported as a component of equity separate from the Parent’s equity, and purchases or sales of equity interests that do not result in a change in control will be accounted for as equity transactions. In addition, net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the income statement and upon a loss of control, the interest sold, as well as any interest retained, will be recorded at fair value with any gain or loss recognized in earnings. This pronouncement is effective for fiscal years beginning after December 15, 2008. We are currently evaluating the impact of adopting FAS 160 on our consolidated results of operations and financial condition and plan to adopt it as required in the first quarter of fiscal 2010.

In February 2007, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities—Including an Amendment of FASB Statement No. 115*, (“FAS 159”). FAS 159 allows an entity the irrevocable option to elect fair value for the initial and subsequent measurement for certain financial assets and liabilities under an instrument-by-instrument election. Most of the provisions in FAS 159 are elective; however, it applies to all companies with available-for-sale and trading securities. A company will report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. FAS 159 is effective for fiscal years beginning after November 15, 2007, with early adoption permitted provided that the entity also adopts FAS 157. We adopted FAS 159 as required at the beginning of our fiscal year 2008 and the adoption did not have a material effect on our consolidated financial statements.

Three and Nine Months Ended September 30, 2008 Compared to Three and Nine Months Ended September 30, 2007

Software and Related Services

Software and related services revenue for the three months ended September 30, 2008 increased \$12,828, or 21.7%, from \$58,985 during the three months ended September 30, 2007 to \$71,813 during the same period in 2008. Software and related services revenue for the nine months ended September 30, 2008 increased \$33,704, or 20.4%, from \$164,906 during the nine months ended September 30, 2007 to \$198,610 during the same period in 2008. The quarterly increase is attributable to software revenue contributed by ECIN, which we acquired on December 31, 2007, an increase of approximately \$3,900 in sales to smaller physician practices and emergency department customers, an increase of approximately \$2,000 in support and maintenance revenue due to the increase in our installed customer base, an increase of approximately \$1,500 in software and implementation services revenue accounted for under percentage of completion and other related services. These increases were partially offset by a decrease in add-on license revenue of approximately \$1,100. The nine month increase is due to software revenue contributed by ECIN which was absent in 2007, an increase of \$12,300 in sales to smaller physician practices and emergency department customers and an increase of approximately \$5,200 in support and maintenance revenue, partially offset by a decrease in add-on license revenue of approximately \$3,700.

Gross profit for software and related services increased \$4,796, or 14.1%, from \$33,968 during the third quarter of 2007 to \$38,764 in the same period of 2008. Gross profit also increased \$14,965, or 15.8%, from \$94,710 in the first nine months of 2007 to \$109,675 in the same period of 2008. The increase in gross profit for both periods is primarily a result of an increase in support and maintenance revenue which is traditionally higher-margin relative to other revenue streams and due to the ECIN margin contribution for the three and nine month periods ended September 30, 2008, which were not present in 2007. Gross profit for software and related services as a percentage of revenue decreased from 57.6% during the third quarter of 2007 to 54.0% in the third quarter of 2008. Gross profit for software and related services as a percentage of revenue decreased from 57.4% during the first nine months of 2007 to 55.2% in the same period of 2008. The decrease in gross profit as a percentage of revenue for both periods was negatively affected by the incremental deployment cost associated with our TouchWorks version 11.0 software and due to an increase in capitalized software amortization on a year-over-year basis.

Operating expenses for software and related services for the third quarter ended September 30, 2008 increased \$301, or 1.8%, from \$16,971 in the third quarter of 2007 to \$17,272 in the same period of 2008. Operating expenses for software and related services for the nine months ended September 30, 2008 increased \$9,535, or 21.6%, from \$44,074 in the first nine months of 2007 to \$53,609 in the same period of 2008. The net increase in operating expenses during the third quarter of 2008 compared to the same period in 2007 is primarily the result of an increase in compensation-related costs of approximately \$1,200 due to increased headcount resulting

[Table of Contents](#)

from the growth of the business and the addition of ECIN employees and an increase in bonus expense as well as an increase in bad debt of approximately \$200, partially offset by a decrease of approximately \$500 in promotional and marketing costs and a decrease of approximately \$200 in travel and consulting costs combined. The nine month increase in operating expenses is primarily due to an increase in compensation-related expenses of approximately \$4,000 attributable to an increase in headcount including ECIN employees, an increase of approximately \$1,700 in bad debt expense and an increase in travel expenses of approximately \$500.

We had capitalized software costs of \$9,514 during the first nine months of 2008 and \$9,043 for the same period in 2007, which was capitalized pursuant to Statement of Financial Accounting Standard "SFAS" No. 86, "Accounting for Costs of Computer Software to be Sold, Leased or Otherwise Marketed" in our software and related services segment. The increase in capitalized software is due to the addition of capitalized software related to our ECIN business, which was absent in the same period of 2007, as well as the on-going development of TouchWorks and Healthmatics products.

Prepackaged Medications

Prepackaged medications revenue for the three months ended September 30, 2008 decreased \$913, from \$10,904 in 2007 to \$9,991 in the same period of 2008. Prepackaged medications revenue for the nine months ended September 30, 2008 decreased \$2,993, from \$32,072 in 2007 to \$29,079 in the same period of 2008. The quarterly decrease is primarily due to an overall decrease in average selling prices for medications due to increased competitive factors, management's focus on reducing lower-margin revenue from wholesaler customers, and due to a decrease in medication orders as a result of increased order monitoring and related restrictions experienced in 2008. Approximately \$800 of the year-over-year decrease was due to the reduction in medication prices and the effect of increased order monitoring and the remaining decrease of approximately \$100 is due to a reduction in wholesaler revenue during the third quarter of 2008 in comparison to the same period in 2007. Of the nine month decrease, approximately \$1,700 was attributed to the reduction in medication prices and the effect of increased order monitoring and approximately \$1,300 was due to a reduction in wholesaler revenue in the nine months ended September 30, 2008 when compared to the same period in 2007.

Gross profit for prepackaged medications for the three months ended September 30, 2008 decreased 4.4%, from \$1,681 in the third quarter of 2007 to \$1,607 in the same period of 2008. Gross profit for prepackaged medications for the nine months ended September 30, 2008 decreased 3.1%, from \$5,400 in the first nine months of 2007 to \$5,234 in the same period of 2008. Gross profit as a percentage of revenue increased from 15.4% in the third quarter of 2007 to 16.1% in the same period of 2008. Gross profit as a percentage of revenue increased from 16.8% in the first nine months of 2007 to 18.0% in the same period of 2008. The increase in gross profit as a percentage of revenue for both periods is primarily due to the reduction in lower-margin revenue from wholesaler customers experienced in the first nine months of 2008.

Operating expenses for prepackaged medications for the quarter ended September 30, 2008 decreased by \$159, from \$919 in 2007 to \$760 in 2008. Operating expenses for prepackaged medications for the first nine months of the year decreased \$213, from \$2,459 in 2007 to \$2,246 in 2008. The third quarter decrease is primarily due to a decrease in compensation costs of approximately \$100. The nine month decrease is due to a decrease in bad debt expense of approximately \$150 and a decrease in consulting expense of \$50, offset by an increase in compensation expense of \$50.

Unallocated Corporate Expenses

Unallocated corporate expenses for the three months ended September 30, 2008 increased by \$7,168 from \$10,844 in the third quarter of 2007 to \$18,012 in the same period in 2008. Unallocated corporate expenses for the nine months ended September 30, 2008 increased by \$16,286 from \$32,924 in the first nine months of 2007 to \$49,210 in the same period in 2008. Excluding approximately \$5,403 in acquisition related expenses relating to the transactions contemplated by the Merger Agreement with Misys plc and other integration related expenses, unallocated corporate expenses for the third quarter of 2008 increased by \$1,765. This increase primarily relates to an increase in compensation related costs of \$1,500 resulting from an increase in headcount and the ECIN acquisition, an increase in deal related amortization of \$700 relating to the ECIN acquisition, offset by a decrease of approximately \$500 in consulting expense. The increase for the nine months ended September 30, 2008 is largely attributable to Misys transaction and other integration related expenses totaling \$11,069. The remaining increase of \$5,217 is due to an increase in compensation-related expenses of \$2,100 resulting from an increase in headcount including ECIN employees, an additional \$2,400 of intangible amortization related to the ECIN acquisition and an increase of approximately \$500 in facilities expenses.

Interest Income and Interest Expense

Interest and other income recognized during the third quarter of 2008 decreased \$806, from \$934 in the third quarter of 2007 to \$128 in the comparable period in 2008. Interest and other income recognized during the first nine months of 2008 decreased \$2,007, from \$3,077 in the first nine months of 2007 to \$1,070 in the comparable period in 2008. The decrease in interest income for both periods is attributed to the net cash of \$38,252 used for the purchase of ECIN as of December 31, 2007, which represents total net cash used of \$88,252 less \$50,000 borrowed under the Credit Facility and due to a decrease in effective interest rates for each comparable period.

[Table of Contents](#)

Interest expense recognized during the three months ended September 30, 2008 increased \$633, from \$927 in the third quarter of 2007 to \$1,560 in the same period in 2008. Interest expense recognized during the first nine months of 2008 increased \$1,797, from \$2,790 in the first nine months of 2007 to \$4,587 in the same period in 2008. The increase in interest expense for both periods is due to the new Credit Facility we entered into on December 31, 2007 which provides for a total unsecured commitment of \$75,000 and matures on August 15, 2012. As of September 30, 2008, \$50,000 in borrowings were outstanding under the Credit Facility and the net proceeds received were used towards the net cash purchase price of \$88,252 related to the purchase of ECIN as of December 31, 2007.

Gain on sale of equity investment

During the third quarter of 2007 we entered into an Option Purchase Agreement with Medem and agreed to sell to Medem for a total purchase price of \$2,592 an irrevocable three-year option held by Allscripts to purchase additional shares of Medem's common stock. The sale of the option resulted in a gain of approximately \$2,392 and is recorded in our operating results for the three and nine months ended September 30, 2007.

Income taxes

Tax provisions related to continuing operations of \$1,123 and \$2,770 were recorded for the three months ended September 30, 2008 and 2007, respectively and \$2,460 and \$9,317 for the nine months ended September 30, 2008 and 2007, respectively. Tax provisions related to discontinued operations of \$165 and (\$20) were recorded for the three months ended September 30, 2008 and 2007, respectively and \$381 and \$402 for the nine months ended September 30, 2008 and 2007, respectively.

Discontinued Operations

On September 17, 2008, Allscripts entered into an Asset Purchase Agreement with Perseus Acquisition, Inc. ("Perseus"), pursuant to which Allscripts agreed to sell to Perseus the assets of the Physicians Interactive business which provide clinical education and information solutions for physicians and patients. The purchase price for the Physicians Interactive business was \$11,500 in cash. The closing of the sale of the Physicians Interactive business occurred on September 30, 2008.

Income from discontinued operations for the three months ended September 30, 2008 increased \$2,272, from (\$28) in the third quarter of 2007 to \$2,244 in the same period of 2008. Income from discontinued operations for the nine months ended September 30, 2008 increased \$1,977, from \$604 in the first nine months of 2007 to \$2,581 in the same period of 2008. The increase for both periods includes a gain of \$1,985 on the disposal of the Physicians Interactive business, net of tax. Excluding the gain on the sale of our information services segment, income from discontinued operations increased by \$287 and decreased by (\$8) for the three and nine months ended September 30, 2008, respectively. The quarterly increase is primarily attributed to an increase in revenue from e-Detailing sessions of approximately \$700 offset by a slight decrease in revenue related to the development and hosting of several PRMP solutions.

Liquidity and Capital Resources

At September 30, 2008 and December 31, 2007, our principal sources of liquidity consisted of cash, cash equivalents and marketable securities of \$79,469 and \$63,003, respectively. The increase of \$16,466 is reflective of the following:

Operating activities

For the nine months ended September 30, 2008, we generated \$29,037 in net cash provided by operations, compared to \$8,515 in the same period of 2007. This net improvement of \$20,522 is due primarily to an increase of approximately \$7,200 in depreciation and amortization expense due to the contribution of the ECIN acquisition, an improvement in accounts receivable management which improved by approximately \$4,600 for the first nine months of 2008 due to management's focus on cash collections and also due to an increase in payments related to prepaid expenses of approximately \$7,600 during the first nine months of 2008 compared to the same period in 2007. There was also an improvement of approximately \$5,000 in accounts payable and accrued expenses due to the timing of vendor and employee payments and an improvement in deferred revenue of approximately \$6,300 due to an increase in customer billing during the nine months ended September 30, 2008. During the first nine months of 2007 we prepaid \$1,700 for third-party software development and other miscellaneous prepayments that were all absent in the same period in 2008. These operating cash flow improvements were partially offset by a decrease of approximately \$8,200 in net income.

Investing activities

We received net proceeds of \$11,104 for the sale of our Physicians Interactive business in a transaction which closed on September 30, 2008. During the first nine months of 2008, we used \$7,135 of cash for capital expenditures and \$8,760 for capitalized software development costs. In addition, we made additional ECIN acquisition payments of \$9,660.

[Table of Contents](#)

During the nine months ended September 30, 2007, we acquired a number of customer contracts from SourceMedical for \$11,331. We used \$6,113 and \$10,104 in the nine months ended September 30, 2007 to fund capital expenditures and capitalized software costs, respectively, which was offset with a gain of \$2,592 from the sale of an equity interest in Medem.

Financing activities

During the nine months ended September 30, 2008, we received \$2,063 in proceeds from the exercise of stock options and purchases of stock under our employee stock purchase plan, compared to the receipt of \$8,655 during the same period in 2007.

Allscripts' working capital increased by \$28,528 or 38.0%, for the nine months ended September 30, 2008, from \$75,067 at December 31, 2007 to \$103,595 at September 30, 2008. The increase is primarily due to an increase in cash and short-term marketable securities of \$27,080 resulting primarily from cash generated from operations and the maturities of long-term securities, an increase in net accounts receivable of \$14,209 and an increase in inventories of \$1,015 attributed to an increase in purchases of hardware to be resold to customers during the first nine months of 2008 and a decrease of \$2,866 in accounts payable and accrued expenses. The increases in working capital are offset by a decrease in deferred taxes of \$11,191 and an increase in deferred revenue of approximately \$8,385. At September 30, 2008, we had an accumulated deficit of \$506,794, compared to \$513,242 at December 31, 2007.

Discontinued Operations

Cash flows from discontinued operations are combined with cash flows from continuing operations within each category on the consolidated cash flow statement. The discontinued operations cash flows are not separately identified as cash flows from discontinued operations within the operating, investing, or financing activities but are presented below. We do not expect the disposal of our information services segment to have a significant impact on future liquidity and capital resources.

	<u>For the nine months ended September 30, 2008</u>
Physicians Interactive operating cash flows	\$ 696
Physicians Interactive investing cash flows	(\$ 696)
Physicians Interactive financing cash flows	\$ —

Future Capital Requirements

On August 15, 2008, Allscripts and its subsidiaries entered into an Amended and Restated Credit Agreement (the "Credit Facility") with JPMorgan Chase Bank, N.A., as the sole administrative agent. The Credit Facility amends and restates the Original Credit Facility. The Credit Facility provides for a total unsecured commitment of \$75,000, an increase of \$15,000 from the Original Credit Facility, and matures on August 15, 2012. The Credit Facility is available in the form of letters of credit and revolving loans.

The Credit Facility also provides a backstop facility of up to \$50,000 (the "Backstop") to be used to fund any repurchases of Allscripts' 3.50% Convertible Senior Debentures (the "Debentures") arising by reason of the Transactions.

On November 7, 2008, Allscripts launched an offer to purchase for cash all of its \$27,868 Debentures outstanding at a purchase price equal to 100% of the principal amount of the Debentures being repurchased (\$1,000 per each \$1,000 principal amount outstanding) plus any accrued and unpaid interest, pursuant to the terms of the indenture governing the Debentures. Allscripts expects to use the Backstop to fund any purchases of the Debentures.

Apart from our use of the Backstop to fund any purchases of the Debentures, we believe that our cash, cash equivalents and marketable securities of \$79,469 as of September 30, 2008 and our cash flow from operations will be sufficient to meet the anticipated cash needs of our business for the next twelve months. In addition to purchasing any Debentures, our primary needs for cash over the next twelve months will be to fund working capital, service approximately \$4,604 in interest payments on our debt instruments, pay acquisition expenses related to the Transactions with Misys plc, fund capital expenditures, contractual obligations, including the Memorandum of Understanding dated as of October 9, 2008 with Misys, regarding a Shared Services Agreement to be entered into between Allscripts-Misys and Misys, and investment needs of our current business.

[Table of Contents](#)

We cannot provide assurance that our actual cash requirements will not be greater than we expect as of the date of this report. We will, from time to time, consider the acquisition of, or investment in, complementary businesses, products, services and technologies, which might impact our liquidity requirements or cause us to issue additional equity or debt securities.

If sources of liquidity are not available or if we cannot generate sufficient cash flow from operations during the next twelve months, we might be required to obtain additional sources of funds through additional operating improvements, capital market transactions, asset sales or financing from third parties, a combination thereof or otherwise. We cannot provide assurance that these additional sources of funds will be available or, if available, would have reasonable terms.

Off Balance Sheet Arrangements

In connection with the corporate facilities lease agreement, Allscripts has provided to the lessor an unconditional irrevocable letter of credit in favor of the lessor in the amount of \$500 as security for the full and prompt performance by Allscripts under the lease agreement. The letter of credit may be drawn upon by the lessor and retained, used or applied by lessor for the purpose of curing any monetary default or defaults of Allscripts under the lease. The letter of credit provides for an expiration date of one year from the commencement date of the lease, and will automatically extend for additional successive one-year periods through the term of the lease. As of September 30, 2008 and 2007, no amounts had been drawn on the letter of credit.

In connection with our acquisition of ECIN, we assumed a \$100 irrevocable letter of credit with a lending institution. A security deposit in the form of a letter of credit is specified in ECIN's Chicago office lease agreement. The letter of credit contains an automatic renewal provision that requires notice of non-renewal to the beneficiary no later than 60 days prior to the current expiration date. The letter of credit expires on June 30, 2009. Under the ECIN Chicago office lease agreement, we have the right to reduce the letter of credit over time to \$75 on November 1, 2008 and to \$50 on November 1, 2009. As of September 30, 2008, no amounts had been drawn on the letter of credit.

We have other letters of credit as security for full and prompt performance under various contractual arrangements totaling \$375. As of September 30, 2008 and 2007, no amounts had been drawn on the letter of credit.

CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. Forward-looking statements include all statements other than those made solely with respect to historical fact. Forward-looking statements may be identified by words such as "believes", "expects", "anticipates", "estimates", "projects", "intends", "should", "seeks", "future", "continue", or the negative of such terms, or other comparable terminology. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Such forward-looking statements are subject to numerous risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from those expressed in or indicated by them.

Factors that could cause actual results to differ materially include, but are not limited to:

- the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that products will not achieve or sustain market acceptance;
- the timing, cost and success or failure of new product and service introductions, development and product upgrade releases;
- competitive pressures including product offerings, pricing and promotional activities;
- our ability to establish and maintain strategic relationships;
- undetected errors or similar problems in our software products;
- compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of the Company's software by the U.S. Food and Drug Administration;
- the possibility of product-related liabilities;
- our ability to attract and retain qualified personnel;
- maintaining our intellectual property rights and litigation involving intellectual property rights;
- risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology;
- the outcome of any legal proceeding that has been or may be instituted against Allscripts, Misys or MHS and others following announcement of entry into the Merger Agreement;
- risks that the Transactions disrupt current plans and operations and potential difficulties in employee retention as a result of the Transactions;

[Table of Contents](#)

- the ability to successfully integrate MHS into Allscripts;
- the ability to recognize the benefits of the Merger;
- legislative, regulatory and economic developments; and
- those factors discussed in “Risk Factors” in Allscripts’ periodic filings with the SEC.

Because forward-looking statements are subject to assumptions and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Stockholders are cautioned not to place undue reliance on such statements, which speak only as of the date such statements are made.

Except to the extent required by applicable law or regulation, Allscripts undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2008, we did not own any derivative financial instruments, but we were exposed to market risks, primarily changes in U.S. and LIBOR interest rates. Our Senior Convertible Debentures and secured promissory note bear a fixed interest rate, and accordingly, the fair market value of the debt is sensitive to changes in interest rates. Allscripts is also exposed to the risk that our earnings and cash flows could be adversely impacted by fluctuations in interest rates due to the \$50,000 loan outstanding under our Credit Facility. Based upon our balance of \$50,000 of debt against our Credit Facility as of September 30, 2008, an increase in interest rates of 1.0% would cause a corresponding increase in our annual interest expense of approximately \$500.

As of September 30, 2008, we had cash, cash equivalents and marketable securities in financial instruments of \$79,469. Declines in interest rates over time will reduce our interest income from our investments. Based upon our balance of cash, cash equivalents and marketable securities as of September 30, 2008, a decrease in interest rates of 1.0% would cause a corresponding decrease in our annual interest income of approximately \$795.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

As of September 30, 2008, our management, including our Chief Executive Officer and Chief Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based on their review and evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are adequate and effective.

Changes in Internal Control

During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Exchange Act Rules 13a-15(f)) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 1. Legal Proceedings.

On September 15, 2008, Allscripts received notice that LaSalle Bank N.A., solely in its capacity as indenture trustee (“LaSalle”), filed a complaint in the Supreme Court of the State of New York, County of New York, on behalf of the holders of Allscripts’ 3.50% Convertible Senior Debentures Due 2024 seeking payment of the “Additional Shares” (as defined in the Indenture dated as of July 6, 2004 between LaSalle and Allscripts in connection with the Transactions). On October 29, 2008, Allscripts filed a motion to dismiss the complaint. Allscripts believes that the complaint is without merit and will vigorously contest the claims set forth in the complaint.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

ISSUER PURCHASES OF EQUITY SECURITIES
(Share amounts in thousands)

<u>Period</u>	(a) Total Number of Shares Purchased (1)	(b) Average Price Paid per Share
July 1, 2008 – July 31, 2008	2	\$12.28
August 1, 2008 – August 31, 2008	5	\$13.65
September 1, 2008 – September 30, 2008	—	\$—
Total	7	\$13.22

(1) Shares withheld for tax liabilities upon vesting of restricted stock awards.

Item 4. Submission of Matters to a Vote of Security Holders

At Allscripts' Annual Meeting of Stockholders held on October 6, 2008, the stockholders (1) approved the issuance of shares of Allscripts common stock in connection with (i) the merger of Patriot Merger Company, a wholly-owned subsidiary of Allscripts, with and into Misys Healthcare Systems, an indirect wholly-owned subsidiary of Misys, with Misys Healthcare continuing as a surviving wholly-owned subsidiary of Allscripts, and (ii) the cash payment by Misys or one of its subsidiaries of approximately \$330,000,000; (2) approved the amendment and restatement of the certificate of incorporation of Allscripts as set forth in Annex B to the proxy statement related to such annual meeting; (3) approved the additional amendment and restatement of the certificate of incorporation and by-laws of Allscripts as set forth in Annex C to the proxy statement related to such annual meeting; (4) elected Glen Tullman and M. Fazle Husain as directors of Allscripts to hold office until the 2011 annual meeting of stockholders (subject to the election and qualification of their successors or their earlier death, resignation or removal); and (5) ratified the appointment of Grant Thornton LLP as Allscripts' independent registered public accounting firm for 2008. The votes were as follows:

	<u>Votes for</u>	<u>Votes Against</u>	<u>Withheld/Abstain</u>	<u>Broker Non-vote</u>
(1) Share issuance in connection with the merger of Patriot Merger Company into Misys Healthcare Systems	40,907,600	403,165	545,857	9,451,237
(2) Amendment and restatement of the certificate of incorporation of Allscripts as set forth in Annex B to the proxy statement	40,920,729	389,043	546,850	9,451,237
(3) Additional amendment and restatement of the certificate of incorporation and by-laws of Allscripts as set forth in Annex C to the proxy statement	50,129,948	604,712	573,289	—
(4) Election of directors:				
Glen Tullman	49,720,596	—	1,587,353	—
M. Fazle Husain	50,414,959	—	892,990	—
(5) Ratification of the appointment of Grant Thornton LLP	50,601,320	136,795	569,833	—

Item 5. Other Information

On November 6, 2008, Allscripts-Misys Healthcare Solutions, Inc. ("Allscripts-Misys") entered into an Employment Agreement (the "Employment Agreement") with Laurie McGraw, the president of its Enterprise Clinical Solutions Group. The Employment Agreement, which is effective as of the closing date of the transactions with Misys plc (the "Transactions"), which was October 10, 2008, supersedes in its entirety Ms. McGraw's prior employment agreement, dated as of January 31, 2003, as amended, and provides the following compensation, benefits, terms and conditions:

- Ms. McGraw will receive a base salary of \$325,000 and will have an annual target bonus opportunity of 75% of her salary.
- Ms. McGraw received a restricted stock unit award following the consummation of the Transactions. The award had a grant-date value of \$1,500,000, and will vest over four years in accordance with Allscripts-Misys' customary vesting schedule. Up to 20% of such award may be made under an equity program of Misys. The portion of the award that entitles Ms. McGraw to receive shares of Allscripts-Misys common stock will be subject to the approval of the stockholders of each of Allscripts-Misys and Misys (the "Conditional Award"). If such approvals have not been obtained on the day prior to each of the first four anniversaries of the grant date of the Conditional Award, and Ms. McGraw has remained continuously employed, one-quarter of the Conditional Award (and any rights or obligations arising therefrom) shall be canceled as of each such anniversary date without payment or other consideration therefor except that Allscripts-Misys shall pay Ms. McGraw, on the tenth day after each such anniversary, a cash lump sum equal to the number of shares of Allscripts-Misys common stock underlying the Conditional Award so canceled on such anniversary day multiplied by the closing price per share of Allscripts-Misys' common stock on the business day next following the applicable anniversary.
- A transaction bonus that vested upon the closing of the Transactions will be paid to Ms. McGraw as a cash lump sum on January 2, 2009, in the amount of \$413,950. Such transaction bonus amount will be deposited into a "rabbi trust" and accumulate interest calculated at the short-term applicable Federal Rate for October 2008.
- Allscripts-Misys will pay a \$73,050 cash award to Ms. McGraw on the tenth day after the first anniversary of the closing of the Transactions unless, prior to such anniversary, Allscripts-Misys terminates her employment without "cause" or Ms. McGraw terminates her employment

without a “constructive discharge” (as such terms are defined in the Employment Agreement).

Termination Without Cause or for Constructive Discharge. The Employment Agreement provides the following benefits upon a termination of Ms. McGraw’s employment by Allscripts-Misys without “cause” or by Ms. McGraw for a “constructive discharge” (except during the two-year period following a change in control of Allscripts-Misys):

- payment of any unpaid performance bonus in respect of the prior fiscal year;
- payment, in installments over 12 months, of the sum of Ms. McGraw’s base salary and target performance bonus; provided, however, that these payments are made only if the termination is after the first anniversary of the closing of the Transactions;
- continuation of health benefits for 12 months; and
- if such termination is after the first anniversary of the closing of the Transactions, pro-rata vesting of the stock award granted to Ms. McGraw equal to (i) the number of shares of such award that would vest on the normal vesting date multiplied by (ii) a fraction, the numerator of which is the number of days elapsed since the last regular vesting date of such award (or grant date if no vesting date has occurred), and the denominator of which is the number of days between the last regular vesting date (or grant date if no vesting date has occurred) and the normal vesting date.

A “constructive discharge” under the Employment Agreement generally means a failure of Allscripts-Misys to meet its obligations in any material respect under such agreement, including, without limitation, a reduction of or failure to pay base salary, a material diminution in or other substantial adverse alteration in the nature or scope of Ms. McGraw’s responsibilities, or the relocation of Ms. McGraw’s principal place of business by more than 50 miles.

Payments Upon a Change of Control; Severance Upon Termination Following a Change of Control. The Employment Agreement provides that Ms. McGraw will receive the following upon the occurrence of a change of control of Allscripts-Misys (other than the Transactions) if she has remained continuously employed by Allscripts-Misys through the effective date of such change of control:

- full vesting of all unvested equity awards;
- a lump sum cash payment equal to the sum of her base salary and target bonus amount;
- an additional lump sum equal to the sum of her base salary and target bonus amount, but only if Allscripts-Misys or representatives of the third party effecting such change of control do not offer Ms. McGraw a comparable job to be held after such change of control, regardless of whether she remains employed by Allscripts-Misys or its successor following such change of control;
- if Ms. McGraw’s employment is terminated without cause or due to constructive discharge during the two-year period following such change of control, a lump sum cash payment equal to the excess of the sum of her base salary and target bonus amount over the amount of any payment made to Ms. McGraw in connection with the lack of a “comparable job” offer and continuation of health benefits for twelve (12) months; and
- A gross-up payment in the event that any payment received in connection with such change in control and/or termination of Ms. McGraw’s employment is subject to “golden parachute” excise taxes and interest or penalties related thereto.

A “comparable job” under the Employment Agreement means employment following a change of control (i) with substantially the same duties and responsibilities as Ms. McGraw held immediately prior to the change of control, (ii) within 50 miles of the location at which she provides services prior to such change of control and (iii) at the same or increased base salary and target performance bonus level as were in effect prior to such change of control

Noncompetition and Nonsolicitation. The Employment Agreement provides for a one-year noncompetition and nonsolicitation period following the termination of Ms. McGraw’s employment.

Ownership of Allscripts-Misys Common Stock. The Employment Agreements requires that Ms. McGraw maintain a minimum ownership level of shares of Allscripts-Misys common stock (including stock options, restricted stock and restricted stock units) equal to: (i) 100% of her base salary as of the consummation of the Transaction (the “Measurement Salary”), for the period from October 10, 2008, until October 9, 2009, (ii) 66% of her Measurement Salary, for the period from October 10, 2009, until October 9, 2010, and (iii) 33% of her Measurement Salary, for the period from October 10, 2010, until October 10, 2011. The failure of Ms. McGraw to maintain the required level of ownership could result in the termination of her employment by Allscripts-Misys for “cause.”

The foregoing description of Ms. McGraw’s Employment Agreements is qualified in its entirety by reference to the full text of such agreement, which has been filed as Exhibit 10.10 to this report, and is incorporated herein by reference.

Item 6. Exhibits

(a) Exhibits

See Index to Exhibits.

INDEX TO EXHIBITS

Exhibit 3.1	Second Amended and Restated Certificate of Incorporation of Allscripts-Misys Healthcare Solutions, Inc. (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 3.2	Amended and Restated By-Laws of Allscripts-Misys Healthcare Solutions, Inc. (incorporated by reference to Exhibit 3.1 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 10.1	Memorandum of Understanding regarding Shared Services Agreement dated as of October 9, 2008 and entered into on October 10, 2008 (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 10.2	Trademark and Trade Name License Agreement dated as of October 10, 2008 between Misys plc and Misys Healthcare Systems, LLC (incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 10.3	Trademark and Trade Name Sublicense Agreement dated as of October 10, 2008 between Misys Healthcare Systems, LLC and Allscripts Healthcare Solutions, Inc. (incorporated by reference to Exhibit 10.3 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 10.4	Proprietary Software License Agreement dated as of October 10, 2008 between Misys Open Source Solutions LLC and Misys Healthcare Systems, LLC (incorporated by reference to Exhibit 10.4 to the registrant's Current Report on Form 8-K filed with the SEC on October 17, 2008)
Exhibit 10.5	Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the SEC on October 23, 2008)
Exhibit 10.6	Separation Agreement and General Release between Allscripts, LLC and Benjamin Bulkley dated September 18, 2008 (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the SEC on September 19, 2008)
Exhibit 10.7	Contract of Purchase and Sale made and entered into on August 20, 2008 by and between A4 Realty, LLC, Ginkgo Square Associates, LLC and Surety Title Company (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the SEC on August 29, 2008)
Exhibit 10.8	Amended and Restated Credit Agreement, dated August 15, 2008, by and among Allscripts Healthcare Solutions, Inc., Allscripts, LLC, A4 Health Systems, Inc., A4 Realty, LLC, Extended Care Information Network, Inc. each as Borrower, the Lenders from time to time parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and J.P. Morgan Securities Inc., as lead arranger (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed with the SEC on August 20, 2008)
Exhibit 10.9	First Amendment to Relationship Agreement dated August 14, 2008 between Allscripts Healthcare Solutions, Inc. and Misys plc (incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed with the SEC on August 20, 2008)
Exhibit 10.10	Employment Agreement entered into on November 6, 2008 and effective as of October 10, 2008, between Allscripts-Misys Healthcare Solutions, Inc. and Laurie McGraw (filed herewith)
Exhibit 10.11	Amendments to the Allscripts Healthcare Solutions, Inc. Amended and Restated 1993 Stock Incentive Plan (filed herewith)
Exhibit 10.12	Amendments to the Allscripts Healthcare Solutions, Inc. 2001 Nonstatutory Stock Option Plan (filed herewith)
Exhibit 31.1	Rule 13a - 14(a) Certification of Chief Executive Officer (filed herewith)
Exhibit 31.2	Rule 13a - 14(a) Certification of Chief Financial Officer (filed herewith)
Exhibit 32.1	Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer (filed herewith)

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (this “**Agreement**”) is made as of this 10th day of October, 2008, by and between Allscripts-Misys Healthcare Solutions, Inc., a corporation organized and existing under the laws of the State of Delaware (“**Company**”) and Laurie McGraw (“**Executive**”).

RECITALS

WHEREAS, Company and Misys Healthcare Systems LLC have entered into an Agreement and Plan of Merger, dated as of March 17, 2008 (the “**Merger Agreement**”), pursuant to which (among other transactions contemplated in the Merger Agreement), at the “**Effective Time**” (as defined in the Merger Agreement), a subsidiary of Company shall be merged with and into Misys Healthcare Systems LLC (such merger, the “**Merger**”);

WHEREAS, Executive currently serves as President – Enterprise Clinical Solutions Group of Company;

WHEREAS, Company desires to continue to employ Executive in such position(s) following the Effective Time, subject to the terms and conditions of this Agreement; and

WHEREAS, Executive desires to be employed by Company in the aforesaid capacity subject to the terms and conditions of this Agreement.

NOW THEREFORE, in consideration of the foregoing premises, of the mutual agreements and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows, effective as of immediately prior to the Effective Time:

AGREEMENT

1. Employment.

Company hereby agrees to employ Executive, and Executive hereby accepts employment, as President, Enterprise Clinical Solutions of Company, pursuant to the terms of this Agreement. Executive shall have the duties and responsibilities and perform such administrative and managerial services of that position as are set forth in the bylaws of Company (the “**Bylaws**”) or as shall be delegated or assigned to Executive by the Chief Executive Officer of Company from time to time. Executive shall carry out her responsibilities hereunder on a full-time basis for and on behalf of Company; provided that Executive shall be entitled to devote time

to outside boards of directors, personal investments, civic and charitable activities, and personal education and development, so long as such activities do not interfere with or conflict with Executive's duties hereunder. Notwithstanding the foregoing, Executive agrees that, during the term of this Agreement, Executive shall not act as an officer of any entity other than Company without the prior written consent of Company.

2. Effective Date and Term.

The term of Executive's employment by Company under this Agreement (the "**Employment Period**") shall commence as of the date on which the Effective Time occurs (the "**Effective Date**") and shall continue in effect through the third anniversary of the Effective Date, unless earlier terminated as provided herein. Thereafter, unless Company or Executive shall elect not to renew the Employment Period upon the expiration of the initial term or any renewal term, which election shall be made by providing written notice of nonrenewal to the other party at least ninety (90) days prior to the expiration of the then current term, the Employment Period shall be extended for an additional twelve (12) months. If Company elects not to renew the Employment Period at the end of the initial term or any renewal term, such nonrenewal shall be treated as a termination of the Employment Period and Executive's employment without Cause by Company for the limited purpose of determining the payments and benefits available to Executive (i.e., Executive shall be entitled to the severance/benefits set forth in Section 4.5.1). If Executive elects not to renew the Employment Period, the same shall constitute a termination of Executive's employment and the Employment Period by Executive without Cause, and Executive shall only be entitled to the payments and benefits set forth in Section 4.5.3.

3. Compensation and Benefits.

In consideration for the services Executive shall render under this Agreement, Company shall provide or cause to be provided to Executive the following compensation and benefits:

3.1 Base Salary. During the Employment Period, Company shall pay to Executive an annual base salary at a rate of \$325,000 per annum, subject to all appropriate federal and state withholding taxes, which base salary shall be payable in accordance with Company's normal payroll practices and procedures. Executive's base salary shall be reviewed annually prior to the beginning of each fiscal year of Company during the Employment Period by the Board of Directors of Company (the "**Board**"), or a committee of the Board, and may be increased in the sole discretion of the Board, or such committee of the Board, based on Executive's performance during the preceding Fiscal Year. For purposes of this Agreement, the term "**Fiscal Year**" shall mean the fiscal year of Company. Executive's base salary, as such base salary may be increased annually hereunder, is hereinafter referred to as the "**Base Salary.**"

3.2 Performance Bonus.

3.2.1 Executive shall be eligible to receive cash bonuses in accordance with this Section 3.2 (each a "**Performance Bonus**"). Payment of any Performance Bonus will be subject to the sole discretion of the Board or a committee of the Board in consultation with the Chief Executive Officer, and the amount of any such Performance Bonus will be determined by, and

based upon criteria selected by, the Board or such committee in consultation with the Chief Executive Officer. Based upon the foregoing exercise of discretion, Executive's target Performance Bonus shall be 75% of her salary (the "Target Performance Bonus"), but may, based on performance, exceed such amount. Performance Bonuses shall be paid according to the terms of the bonus plan or program in which Executive participates from time to time; provided that any Performance Bonus for the period ending on the Effective Date shall be payable in calendar year 2009.

3.3 Benefits. During the Employment Period and as otherwise provided hereunder, Executive shall be entitled to the following:

3.3.1 Vacation. Executive shall be entitled to twenty (20) business days per Fiscal Year of paid vacation, such vacation time not to be cumulative (i.e., vacation time not taken in any Fiscal Year shall not be carried forward and used in any subsequent Fiscal Year).

3.3.2 Participation in Benefit Plans. Executive shall be entitled to health and/or dental benefits, including immediate coverage for Executive and her eligible dependents, which are generally available to Company's senior executive employees and as provided by Company in accordance with its group health insurance plan coverage. In addition, Executive shall be entitled to participate in any profit sharing plan, retirement plan, group life insurance plan or other insurance plan or medical expense plan maintained by Company for its senior executives generally, in accordance with the general eligibility criteria therein.

3.3.3 Physical Examination. Executive shall be entitled to receive reimbursement for the cost of one general physical examination per twelve (12) month period during the term of the Agreement from a physician chosen by Executive in her reasonable discretion.

3.3.4 Perquisites. Executive shall be entitled to such other benefits and perquisites that are generally available to Company's senior executive employees and as provided in accordance with Company's plans, practices, policies and programs for senior executive employees of Company.

3.3.5 Indemnification. Executive shall be entitled to indemnification (including immediate advancement of all legal fees with respect to any claim for indemnification) and directors' and officers' insurance coverage, to the extent made available to other senior executives, in accordance with the Bylaws and all other applicable policies and procedures of Company.

3.4 Expenses. Company shall reimburse Executive for proper and necessary expenses incurred by Executive in the performance of her duties under this Agreement from time to time upon Executive's submission to Company of invoices of such expenses in reasonable detail and subject to all standard policies and procedures of Company with respect to such expenses.

3.5 Stock Awards. Executive shall be eligible to participate in any applicable stock bonus, stock option, or similar plan implemented by Company and generally available to its senior executive employees. Company intends to recommend to the

Compensation Committee of the Board that Executive be granted an award under a Company stock incentive plan, with a grant-date value of \$1,500,000, which award shall vest in four equal annual installments on the first four anniversaries of the Effective Date. Up to 20% of such grant may be made under an equity plan or program of Misys plc (“**Parent**”) in accordance with the terms and provisions of such equity plan or program. Executive acknowledges and agrees that the portion of such grant relating to Company (as opposed to Parent) common stock (the “**Company Stock Award**”) shall be conditioned upon the establishment of a new Company stock incentive plan or an amendment that increases the number of shares of Company common stock available for award under an existing Company stock incentive plan, and that such establishment or amendment must be approved by the shareholders of Company and Parent, in each case in accordance with the law, rules and regulations applicable to such approvals (the “**Approvals**”). If, on the day prior to each of the first four anniversaries of the grant date of the Company Stock Award (the “**Grant Date**”), Executive has remained continuously employed since the Effective Date, but the shareholder approval conditions described in the previous sentence have not been satisfied, one-quarter of the Company Stock Award (and any rights or obligations arising therefrom) shall be canceled as of each such anniversary day without payment or other consideration therefor except Company shall pay Executive, on the tenth day after each such anniversary, a cash lump sum equal to the number of shares of Company common stock underlying the Company Stock Award so canceled on such anniversary day multiplied by the closing price per share of Company’s common stock on the business day next following the applicable anniversary.

3.6 Consummation and Retention Bonus.

3.6.1 On the later to occur of (i) the tenth day after the Effective Date and (ii) January 2, 2009, Company shall pay Executive a cash lump sum payment equal to \$413,950 (the “**Retention Payment**”). If the Retention Payment is to be made on a date later than the tenth day after the Effective Date as provided above, within 10 days of the Effective Date Company shall establish a “rabbi trust” and deposit the amounts payable under this Section 3.6.1 into such trust, which amounts shall accumulate interest calculated at the short-term Applicable Federal Rate for the month in which the Effective Date occurs and the Retention Payment (including accumulated interest) shall be made from such trust to Executive.

3.6.2 In addition, so long as (i) Executive has remained continuously employed from the Effective Date through the first anniversary of the Effective Date, (ii) Executive’s employment is terminated by Company without Cause prior to the first anniversary of the Effective Date or (iii) Executive terminates employment for Constructive Discharge, Company shall pay Executive a cash lump sum equal to \$73,050, on the tenth day after the first anniversary of the Effective Date.

3.7 Payment upon a Change of Control. So long as Executive has remained continuously employed from the Effective Date through the date of a Change of Control, (i) all unvested Company equity awards held by executive shall vest upon the Change of Control, and (ii) Company shall pay Executive, within ten (10) days following the occurrence of the Change of Control, a cash lump sum equal to the sum of Executive’s Base Salary and Target Performance Bonus. In addition, if a Change of Control occurs, and, prior to the Change of Control, Company or representatives of the third party effecting the Change of Control (as applicable) do not

offer Executive a Comparable Job following the Change of Control, then, so long as Executive has remained continuously employed from the Effective Date through the date of a Change of Control, whether or not Executive continues to be employed by Company or a successor to Company following the Change of Control, Company will pay Executive, within ten (10) days following the occurrence of the Change of Control, an additional cash lump sum equal to the sum of Executive's Base Salary and Target Performance Bonus (the "**Additional Change of Control Payment**"). For purposes of this Agreement, a "**Comparable Job**" shall mean employment following the Change of Control (i) with substantially the same duties and responsibilities as were held by Executive prior to the Change of Control (excluding, for this purpose, changes following the Change of Control (x) to Executive's reporting responsibilities and (y) arising by reason of Company ceasing to be a public company), (ii) at the same location at which Executive provides services prior to the Change of Control or a location within fifty (50) miles of such location and (iii) at the same or increased Base Salary and Target Performance Bonus levels as were in effect prior to the Change of Control.

4. Termination of the Services Prior To the Expiration Date.

Executive's employment hereunder and the Employment Period may be terminated at any time as follows (the effective date of such termination hereinafter referred to as the "**Termination Date**"):

4.1 Termination upon Death or Disability of Executive.

4.1.1 Executive's employment hereunder and the Employment Period shall terminate immediately upon the death of Executive. In such event, all rights of Executive and/or Executive's estate (or named beneficiary) shall cease except for the right to receive payment of the amounts set forth in Section 4.5.4 of the Agreement.

4.1.2 Company may terminate Executive's employment hereunder and the Employment Period upon the disability of Executive. For purposes of this Agreement, Executive shall be deemed to be "disabled" if Executive, as a result of illness or incapacity, shall be unable to perform substantially her required duties for a period of three (3) consecutive months or for any aggregate period of three (3) months in any six (6) month period. In the event of a dispute as to whether Executive is disabled, Company may refer Executive to a licensed practicing physician of Company's choice, and Executive agrees to submit to such tests and examination as such physician shall deem appropriate to determine Executive's capacity to perform the services required to be performed by Executive hereunder. In such event, the parties hereby agree that the decision of such physician as to the disability of Executive's shall be final and binding on the parties. Any termination of the Employment Period under this Section 4.1.2 shall be effected without any adverse effect on Executive's rights to receive benefits under any disability policy of Company, but shall not be treated as a termination without Cause.

4.2 Termination by Company for Cause. Company may terminate Executive's employment hereunder and the Employment Period for Cause (as defined herein) upon written notice to Executive, which termination shall be effective on the date specified by Company in such notice; provided, however, that Executive shall have a period of ten (10) days (or such longer period not to exceed thirty (30) days as would be reasonably required for Executive to cure such action or inaction) after the receipt of the written notice

from Company to cure the particular action or inaction, to the extent a cure is possible. For purposes of this Agreement, the term “ **Cause**” shall mean:

4.2.1 the willful or grossly negligent failure by Executive to perform her duties and obligations hereunder in any material respect, other than any such failure resulting from the disability of Executive;

4.2.2 Executive’s conviction of a crime or offense involving the property of Company, or any crime or offense constituting a felony or involving fraud or moral turpitude; provided that, in the event that Executive is arrested or indicted for a crime or offense related to any of the foregoing, then Company may, at its option, place Executive on paid leave of absence, pending the final outcome of such arrest or indictment;

4.2.3 Executive’s violation of any law, which violation is materially and demonstrably injurious to the operations or reputation of Company;

4.2.4 Executive’s material violation of any generally recognized policy of Company or Executive’s refusal to follow the lawful directions of the Chief Executive Officer, or Executive’s insubordination to her supervisor; or

4.2.5 Executive’s failure during the Employment Period to retain the number shares of Company common stock set forth in Appendix A for a period of more than 30 days.

4.3 Termination without Cause. Either party may terminate Executive’s employment and the Employment Period without Cause upon thirty (30) days’ prior written notice to the other party. Upon termination of Executive’s employment with Company for any reason, Executive shall be deemed to have resigned from all positions with the other members of Company and its subsidiaries (provided, that any such deemed resignations shall not affect Executive’s entitlement (if any) to severance pay and benefits hereunder).

4.4 Termination by Executive for Constructive Discharge.

4.4.1 Executive may terminate Executive’s employment and the Employment Period, in accordance with the process set forth below, a result of a Constructive Discharge. For purposes of this Agreement “ **Constructive Discharge**” shall mean the occurrence of any of the following after the Effective Time:

- (i) a failure of Company to meet its obligations in any material respect under this Agreement, including, without limitation, (x) any reduction in the Base Salary or (y) any failure to pay the Base Salary (other than, in the case of clause (y), the inadvertent failure to pay a de minimis amount of the Base Salary, which payment is immediately made by Company upon notice from Executive);
- (ii) a material diminution in or other substantial adverse alteration in the nature or scope of Executive’s responsibilities with Company from those in effect immediately following the Effective Time (it being understood that Company

will have appointed an Executive Chairman as of the Effective Time who will serve as an officer of Company and take an active role in the management and operation of Company); or

- (iii) Executive has been asked to relocate her principal place of business to a location that is more than fifty (50) miles from Company's offices located at the Merchandise Mart Plaza, Chicago, Illinois.

4.4.2 For purposes of this Agreement, a "**Change of Control**" shall mean any one of the following events following the Effective Date (it being understood that the consummation of the Merger and the other transactions contemplated by the Merger Agreement, individually or collectively, shall not constitute a Change of Control):

- (i) the date of acquisition by any person or group other than Parent or any affiliate of Parent or any subsidiary of the Company (or any employee benefit plans (or related trust) of the Company or any of its subsidiaries or Parent) acquires beneficial ownership of securities possessing more than thirty percent (30%) of the total combined voting power of the Company Group's then outstanding voting securities which generally entitle the holder thereof to vote for the election of directors ("**Voting Power**"), provided, however, that no Change of Control shall be deemed to have occurred solely by reason of any such acquisition by a corporation with respect to which, after such acquisition, more than sixty percent (60%) of the then outstanding shares of common stock of such corporation and the Voting Power of such corporation are then beneficially owned, directly or indirectly, by the persons who were the beneficial owners of the stock and Voting Power of Company immediately before such acquisition, in substantially the same proportions as their ownership immediately before such acquisition; or
- (ii) the date the individuals who constitute the Board as of immediately following the Effective Time (the "**Incumbent Board**") cease for any reason other than their deaths to constitute at least a majority of the Board; provided that any individual who becomes a director after the Effective Time whose election or nomination for election by Company's stockholders was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered, for purposes of this Section, as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of the directors of Company (as such terms are used in Rule 14a-11 under the 1934 Act); or
- (iii) Company effects (a) a merger or consolidation of Company with one or more corporations or entities, as a result of which the holders of the outstanding Voting Stock of Company immediately prior to such merger, reorganization or consolidation hold less than 50% of the Voting Power of the surviving or resulting corporation or entity immediately

after such merger or consolidation; (b) a liquidation or dissolution of Company; or (c) a sale or other disposition of all or substantially all of the assets of Company other than to an entity of which Company owns at least 50% of the Voting Power;

provided, however, that in no event shall the acquisition by any person or group of the beneficial ownership of any amount of stock or voting securities of Parent (including an acquisition by a merger, reorganization or consolidation) constitute a Change of Control.

4.4.3 For purposes of the foregoing definition, the terms “beneficially owned” and “beneficial ownership” and “person” shall have the meanings ascribed to them in SEC rules 13d-5(b) under the 1934 Act, and “group” means two or more persons acting together in such a way to be deemed a person for purposes of Section 13(d) of the 1934 Act. Further, notwithstanding anything herein to the contrary, the definition of Change of Control set forth herein shall not be broader than the definition of “change in control event” as set forth under Section 409A of the Code, and the guidance promulgated thereunder, and if a transaction or event does not otherwise fall within such definition of change of control event, it shall not be deemed a Change of Control for purposes of this Agreement.

4.4.4 In the event of a Constructive Discharge, Executive shall have the right to terminate her employment hereunder and receive the benefits set forth in Section 4.5.1 below, upon delivery of written notice to Company no later than the close of business on the sixtieth (60th) day following the effective date of a Constructive Discharge; provided, however, that such termination shall not be effective until the expiration of thirty (30) days after receipt by Company of such written notice if Company has not cured such Constructive Discharge within the 30-day period. If Company so effects a cure, the Constructive Discharge notice shall be deemed rescinded and of no force or effect. Notwithstanding the foregoing, such notice and lapse of time shall not be required with respect to any event or circumstance which is the same or substantially the same as an event or circumstance with respect to which notice and an opportunity to cure has been given within the previous six (6) months. The effective date of a Constructive Discharge shall be the date of the Executive’s “separation from service” (within the meaning of Treas. Reg. Section 1.409A-1(h)).

4.5 Rights upon Termination. Upon termination of Executive’s employment and the Employment Period, the following shall apply:

4.5.1 Termination by Company Without Cause or for Constructive Discharge. If Company terminates Executive’s employment and the Employment Period without Cause, or if Executive terminates Executive’s employment and the Employment Period as a result of a Constructive Discharge, in each case either (x) prior to a Change of Control, or (y) after the second anniversary of a Change of Control, Executive shall be entitled to receive payment of any Base Salary amounts that have accrued but have not been paid as of the Termination Date, and the unpaid Performance Bonus, if any, with respect to the Fiscal Year preceding the Fiscal Year in which the Termination Date occurs (such Performance Bonus, if any, to be determined in the manner that it would have been determined, and payable at the time it would have been payable, under Section 3.2 had there been no termination of the Employment

Period). In addition, subject to Sections 4.5.2 and 4.7, below, Company shall, subject to Section 10.14, be obligated to pay Executive (or provide Executive with) the following benefits as severance:

- (i) provided such termination is after the first anniversary of the Effective Date, an amount equal to Executive's Base Salary plus Executive's Target Performance Bonus, payable in twelve (12) equal monthly installments commencing on the Termination Date, such amount to be payable regardless of whether Executive obtains other employment and is compensated therefor (but only so long as Executive is not in violation of Section 5 hereof) (with the first two installments to be paid on the sixtieth (60th) day following the Termination Date and the remaining ten (10) installments being paid on the ten following monthly anniversaries of such date);
- (ii) continuation of Executive's then current enrollment (including family enrollment, if applicable) in all health and/or dental insurance benefits set forth in Section 3.2.2 for a period of twelve (12) months following the Termination Date, with Executive's contribution to such plans as if Executive were employed by Company, such contributions to be paid by Executive in the same period (e.g., monthly, bi-weekly, etc.) as all other employees of Company; provided, however that Company may terminate such coverage if payment from Executive is not made within ten (10) days of the date on which Executive receives written notice from Company that such payment is due; and provided, further, that such benefits may be discontinued earlier to the extent that Executive becomes entitled to comparable benefits from a subsequent employer; and
- (iii) provided such termination is after the first anniversary of the Effective Date, upon the Termination Date (or, for awards subject to the satisfaction of a performance condition, subject to the satisfaction of such performance condition and upon the satisfaction of such performance condition, and based on the level of performance achieved) a pro-rata portion of any unvested stock option, restricted stock, restricted stock unit or other equity award granted to Executive pursuant to Section 3.5 equal shall vest, which pro-rata portion shall be equal to (a) the number of shares of such award that would vest on the normal vesting date of such award, multiplied by (b) a fraction, the numerator of which is the number of days elapsed since the last regular vesting date of such award (or the grant date, if no portion of such award has yet vested), and the denominator of which is the number of days between the last regular vesting date (or grant date, as the case may be) and the normal vesting date.

4.5.2 Severance Upon Termination following a Change of Control. If Executive terminates Executive's employment and the Employment Period pursuant to Section 4.4 or Company terminates Executive's employment pursuant to Section 4.3 within the period beginning on the date of a Change of Control and ending on the second anniversary of the Change of Control, then

Executive shall, subject to Section 4.7, be entitled to receive the benefits described in Sections 4.5.1(ii) (but not the payments described in Section 4.5.1(i)) and a lump sum amount of cash equal to (x) the sum of (A) Executive's Base Salary plus (B) Executive's Target Performance Bonus minus (y) the Additional Change of Control Payment, if previously paid to Executive (or, if clause (x) minus clause (y) would produce a negative number, then the payment pursuant to this Section 4.5.2 shall be zero). Subject to Sections 10.14, the lump sum to which Executive is entitled hereunder shall be paid on the sixtieth (60th) day following the Termination Date.

4.5.3 Termination With Cause by Company or Without Constructive Discharge by Executive. If Company terminates Executive's employment and the Employment Period with Cause, or if Executive terminates Executive's employment and the Employment Period other than as a result of a Constructive Discharge, Company shall be obligated to pay Executive (i) any Base Salary amounts that have accrued but have not been paid as of the Termination Date; and (ii) subject to Section 10.14, the unpaid Performance Bonus, if any, with respect to the Fiscal Year preceding the Fiscal Year in which the Termination Date occurs (such Performance Bonus, if any, to be determined in the manner it would have been determined, and payable at the time it would have been payable, under Section 3.2 had there been no termination of the Employment Period).

4.5.4 Termination Upon Death or Disability. If Executive's employment and the Employment Period is terminated because of the death or disability of Executive, Company shall, subject to Section 10.14, be obligated to pay Executive or, if applicable, Executive's estate, the following amounts: (i) earned but unpaid Base Salary; and (ii) the unpaid Performance Bonus, if any, with respect to the Fiscal Year preceding the Fiscal Year in which the Termination Date occurs (such Performance Bonus, if any, to be determined in the manner it would have been determined, and payable at the time it would have been payable, under Section 3.2 had there been no termination of the Employment Period).

4.6 Effect of Notice of Termination. Any notice of termination by Company, whether for Cause or without Cause, may specify that, during the notice period, Executive need not attend to any business on behalf of Company.

4.7 Requirement of a Release; Exclusivity of Severance Payments under this Agreement. As a condition to the receipt of the severance payments and termination benefits to be provided to Executive pursuant to this Section 4 upon termination of Executive's employment, Executive shall execute and deliver to Company a general release of employment claims against Company and its affiliates in a form reasonably satisfactory to Company within forty-five (45) days following the Termination Date (provided, that Executive shall not be required to release any rights under this Agreement). In addition, the severance payments and termination benefits to be provided to Executive pursuant to this Section 4 upon termination of Executive's employment shall constitute the exclusive payments in the nature of severance or termination pay or salary continuation which shall be due to Executive upon a termination of employment and shall be in lieu of any other such payments under any severance plan, program, policy or other arrangement which has heretofore been or shall hereafter be established by Company or any of its affiliates.

5. Noncompetition and Confidentiality.

5.1 Covenant Not to Compete. During the Employment Period and for a period of one (1) year after the expiration or earlier termination of the Employment Period, Executive shall not, **(i)** directly or indirectly act in concert or conspire with any person employed by Company or any of its Subsidiaries in order to engage in or prepare to engage in or to have a financial or other interest in any business which is a Direct Competitor (as defined below); or **(ii)** serve as an employee, agent, partner, shareholder, director or consultant for, or in any other capacity participate, engage or have a financial or other interest in any business which is a Direct Competitor (provided, however, that notwithstanding anything to the contrary contained in this Agreement, Executive may own up to two percent (2%) of the outstanding shares of the capital stock of a company whose securities are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “**1934 Act**”). For purposes of this Agreement, the term “**Direct Competitor**” shall mean any person or entity engaged in the business of marketing or providing within the continental United States prescription products or services for pharmacy benefit management products or services, including, without limitation, (i) prepackaged prescription products or services, (ii) point of care pharmacy dispensing systems, (iii) point of care decision support software for physicians, (iv) mail service pharmacy products or services, (v) pharmaceuticals or pharmaceutical delivery systems, (vi) electronic medical record or practice management software, (vii) homecare, home health or hospice support software, and (viii) electronic processing of healthcare transactions.

5.2 No Solicitation of Employees. During the Employment Period and for a period of one (1) year following the expiration or earlier termination of the Employment Period for any reason, Executive shall not, directly or indirectly, whether for its own account or for the account of any other individual or entity, **(i)** employ, hire or solicit for employment, or attempt to employ, hire or solicit for employment, any Employee (as defined below), **(ii)** divert or attempt to divert, directly or indirectly, or otherwise interfere in a material fashion with or circumvent the relationship of Company or any of its Subsidiaries with, any Employees, or **(iii)** induce or attempt to induce, directly or indirectly, any Employee to terminate her employment or other business relationship with Company or any of its Subsidiaries. For purposes of this Section 5.2, “Employee” shall mean any person who is or was employed by Company or any of its Subsidiaries during the Employment Period; provided, however, that “**Employee**” shall not include any person **(a)** whose employment with Company or a Subsidiary of Company was terminated by Company or such Subsidiary without cause, or **(b)** who was not employed by Company or any of its Subsidiaries at any time during the six (6) month period immediately prior to the Termination Date.

5.3 Confidential Information. Company has advised Executive, and Executive acknowledges, that it is the policy of Company to maintain as secret and confidential all Protected Information (as defined below), and that Protected Information has been and will be developed at substantial cost and effort to Company and its Subsidiaries. Executive shall not at any time, directly or indirectly divulge, furnish or make accessible to any person, firm, corporation, association or other entity (otherwise than as may be required in the regular course of Executive’s employment), nor use in any manner, either during the Employment Period or after the termination of the Employment Period for any reason, any Protected Information, or cause any such information of Company or any of its

Subsidiaries to enter the public domain, except as required by law or court order. “**Protected Information**” means trade secrets, confidential and proprietary business information of Company, and any other information of Company or any of its Subsidiaries, including, without limitation, customer lists (including potential customers), sources of supply, processes, plans, materials, pricing information, internal memoranda, marketing plans, internal policies, and products and services which may be developed from time to time by Company or any of its Subsidiaries and the agents or employees of any of them, including Executive; provided, however, that information that is in the public domain (other than as a result of a breach of this Agreement), approved for release by Company or a Subsidiary (as applicable) or lawfully obtained from third parties who are not bound by a confidentiality agreement with Company or any of its Subsidiaries, is not Protected Information.

5.4 Injunctive Relief. Executive acknowledges and agrees that the restrictions imposed upon her by this Section 5 and the purpose for such restrictions are reasonable and are designed to protect the Protected Information and the continued success of Company without unduly restricting Executive’s future employment by others. Furthermore, Executive acknowledges that in view of the Protected Information of Company and its Subsidiaries which Executive has or will acquire or has or will have access to and the necessity of the restriction contained in this Section 5, any violation of the provisions of this Section 5 would cause irreparable injury to Company and its successors in interest with respect to the resulting disruption in their operations. By reason of the foregoing, Executive consents and agrees that if he violates any of the provisions of this Section 5, Company and its successors in interest, as the case may be, shall be entitled, in addition to any other remedies that they may have, including monetary damages, to an injunction to be issued by a court of competent jurisdiction, restraining Executive from committing or continuing any violation of this Section 5.

6. Certain Additional Payments by Company.

Company agrees that:

6.1 Anything in this Agreement to the contrary notwithstanding, in the event that, following a Change of Control, it shall be determined that any payment or distribution by Company to or for the benefit of Executive (whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, but determined without regard to any additional payments required under this Section 6) (a “**Payment**”) would be subject to the excise tax imposed by Section 4999 of the Code or if any interest or penalties are incurred by Executive with respect to such excise tax (such excise tax, together with any such interest and penalties, being hereafter collectively referred to as the “**Excise Tax**”), then Executive shall be entitled to receive an additional payment (a “**Gross-Up Payment**”) in an amount such that after payment by Executive of all taxes (including interest or penalties imposed with respect to such taxes), including, without limitation, any income taxes (and any interest and penalties imposed with respect thereto) and Excise Tax imposed upon the Gross-Up Payment, Executive retains an amount of the Gross-Up Payment equal to the Excise Tax imposed upon the Payment.

6.2 Subject to the provisions of Section 6.3, below, all determinations required to be made under this Section 6, including whether and when a Gross-Up Payment is required and the amount of such Gross-Up Payment and the assumptions to be utilized in

arriving at such determination, shall be made by the accounting firm which is then serving as the auditors for Company (the “ **Accounting Firm**”), which shall provide detailed supporting calculations both to Company and Executive within fifteen (15) business days of the receipt of notice from Executive that there has been a Payment, or such earlier time as is requested by Company. In the event that the Accounting Firm is serving as accountant or auditor for the individual, entity, or group effecting the Change of Control, Executive shall appoint another nationally recognized accounting firm to make the determinations required hereunder (which accounting firm shall then be referred to as the Accounting Firm hereunder). All fees and expenses of the Accounting Firm shall be borne solely by Company. Any Gross-Up Payment, as determined pursuant to this Section 6, shall be paid by Company to Executive (or to the applicable taxing authority on Executive’s behalf) within five (5) days of the receipt of the Accounting Firm’s determination or, if later, on the due date for such taxes. If the Accounting Firm determines that no Excise Tax is payable by Executive, it shall furnish Executive with a written opinion that failure to report the Excise Tax on Executive’s applicable federal income tax return would not result in the imposition of a negligence or similar penalty. Any good faith determination by the Accounting Firm shall be binding upon Company and Executive. As a result of the uncertainty in the application of Section 4999 of the Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that Gross-Up Payments which will not have been made by Company should have been made (“**Underpayment**”), consistent with the calculations required to be made hereunder. In the event that Company exhausts its remedies pursuant to Section 6.3, below, and Executive thereafter is required to make a payment of any Excise Tax, the Accounting Firm shall determine the amount of the Underpayment that has occurred and any such Underpayment shall be promptly paid by Company to or for the benefit of Executive.

6.3 Executive shall notify Company in writing of any claim by the Internal Revenue Service that, if successful, would require the payment by Company of a Gross-Up Payment. Such notification shall be given as soon as practicable but no later than fifteen (15) business days after Executive is informed in writing of such claim and shall apprise Company of the nature of such claim and the date on which such claim is requested to be paid. Executive shall not pay such claim prior to the expiration of the thirty (30) day period following the date on which Executive gives such notice to Company (or such shorter period ending on the date that any payment of taxes with respect to such claim is due). If Company notifies Executive in writing prior to the expiration of such period that it desires to contest such claim, Executive shall:

6.3.1 Give Company any information reasonably requested by Company relating to such claim;

6.3.2 Take such action in connection with contesting such claim as Company shall reasonably request in writing from time to time, including, without limitation, accepting legal representation with respect to such claim by an attorney reasonably selected by Company;

6.3.3 Cooperate with Company in good faith in order effectively to contest such claim; and

6.3.4 Permit Company to participate in any proceedings relating to such claim; provided, however, that Company shall bear and pay directly all costs and expenses (including additional interest and penalties) incurred in connection with such contest and

shall indemnify and hold Executive harmless, on an after-tax basis, for any Excise Tax or income tax (including interest and penalties with respect thereto) imposed as a result of such representation and payment of costs and expenses. Without limiting the foregoing provisions of this Section 6.3, Company shall control all proceedings taken in connection with such contest and, at its sole option, may pursue or forego any and all administrative appeals, proceedings, hearings and conferences with the taxing authority in respect of such claim and may, at its sole option, either direct Executive to pay the tax claimed and sue for a refund or contest the claim in any permissible manner; and Executive agrees to prosecute such contest to a determination before any administrative tribunal, in a court of initial jurisdiction and in one or more appellate courts, as Company shall determine; provided further, however, that if Company directs Executive to pay such claim and sue for a refund, Company shall advance the amount of such payment to Executive on an interest-free basis and shall indemnify and hold Executive harmless, on an after-tax basis, from any Excise Tax or income tax (including interest or penalties with respect thereto) imposed with respect to such advance or with respect to any imputed income with respect to such advance; and further provided that any extension of the statute of limitations relating to payment of taxes for the taxable year of Executive with respect to which such contested amount is claimed to be due is limited solely to such contested amount. Furthermore, Company's control of the contest shall be limited to issues with respect to which a Gross-Up Payment would be payable hereunder and Executive shall be entitled to settle or contest, as the case may be, any other issue raised by the Internal Revenue Service or any other taxing authority.

6.4 If, after the receipt by Executive of an amount advanced by Company pursuant to Section 6.3 above, Executive becomes entitled to receive any refund with respect to such claim, Executive shall (subject to Company's complying with the requirements of said interest paid or credited thereon, after taxes applicable thereto) promptly pay such refund to Company. If, after the receipt by Executive of an amount advanced by Company pursuant to said Section 6.3, a determination is made that Executive shall not be entitled to any refund with respect to such claim and Company does not notify Executive in writing of its intent to contest such denial of refund prior to the expiration of thirty (30) days after such determination, then such advance shall be forgiven and shall not be required to be repaid; and the amount of such advance shall offset, to the extent thereof, the amount of the Gross-Up Payment required to be paid.

6.5 Subject to any earlier time limits set forth in this Section 6, all payments and reimbursements to which Executive is entitled under this Section 6 shall be paid to or on behalf of Executive not later than the end of the taxable year of Executive next following the taxable year of Executive in which Executive (or Company, on Executive's behalf) remits the related taxes (or, in the event of an audit or litigation with respect to such tax liability, not later than the end of the taxable year of Executive next following the taxable year of Executive in which there is a final resolution of such audit or litigation (whether by reason of completion of the audit, entry of a final and non-appealable judgment, final settlement, or otherwise)).

7. No Set-Off or Mitigation.

Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which Company may have against Executive or others. In no event shall Executive be obligated to seek other employment or take any other action by way of

mitigation of the amounts payable to Executive under any of the provisions of this Agreement and, except as otherwise provided herein, such amounts shall not be reduced whether or not Executive obtains other employment.

8. Payment of Certain Expenses.

Company agrees to pay promptly as incurred and not less than on a monthly basis, to the fullest extent permitted by law, all legal fees and expenses which Executive may reasonably incur as a result of any contest by Company, Executive or others of the validity or enforceability of, or liability under, any provision of the Agreement (including as a result of any contest initiated by Executive about the amount of any payment due pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code; provided, however, that Company shall not be obligated to make such payment with respect to any contest in which Company prevails over Executive, and, in such case, Executive shall return to Company any payments previously paid to or on behalf of Executive.

9. Indemnification.

To the fullest extent permitted by law, Company shall indemnify Executive (including the advancement of expenses) for any judgments, fines, amounts paid in settlement and reasonable expenses, including attorney's fees, incurred by Executive in connection with the defense of any lawsuit or other claim to which Executive is made a party by reason of being an officer, director or employee of Company or any of its Subsidiaries.

10. Miscellaneous.

10.1 Valid Obligation. This Agreement has been duly authorized, executed and delivered by Company and has been duly executed and delivered by Executive and is a legal, valid and binding obligation of Company and of Executive, enforceable in accordance with its terms.

10.2 No Conflicts. Executive represents and warrants that the performance by her of her duties hereunder will not violate, conflict with, or result in a breach of any provision of, any agreement to which he is a party.

10.3 Applicable Law. This Agreement shall be construed in accordance with the laws of the State of Illinois, without reference to Illinois' choice of law statutes or decisions.

10.4 Severability. The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any one or more of the provisions hereof shall not affect the validity or enforceability of any other provision. In the event any clause of this Agreement is deemed to be invalid, the parties shall endeavor to modify that clause in a manner which carries out the intent of the parties in executing this Agreement.

10.5 No Waiver. The waiver of a breach of any provision of this Agreement by any party shall not be deemed or held to be a continuing waiver of such breach or a waiver of any subsequent breach of any provision of this Agreement or as nullifying the effectiveness of such provision, unless agreed to in writing by the parties.

10.6 Notices. All demands, notices, requests, consents and other communications required or permitted under this Agreement shall be in writing and shall be personally delivered or sent by facsimile machine (with a confirmation copy sent by one of the other methods authorized in this Section), or by commercial overnight delivery service, to the parties at the addresses set forth below:

To Company: Allscripts-Misys Healthcare Solutions, Inc.
222 Merchandise Mart Plaza
Suite 2024
Chicago, IL 60654
Attention: Company Secretary or General Counsel

To Executive: At the address or fax number most recently contained in Company's records

Notices shall be deemed given upon the earliest to occur of (i) receipt by the party to whom such notice is directed, if hand delivered; (ii) if sent by facsimile machine, on the day (other than a Saturday, Sunday or legal holiday in the jurisdiction to which such notice is directed) such notice is sent if sent (as evidenced by the facsimile confirmed receipt) prior to 5:00 p.m. Central Time and, if sent after 5:00 p.m. Central Time, on the day (other than a Saturday, Sunday or legal holiday in the jurisdiction to which such notice is directed) after which such notice is sent; or (iii) on the first business day (other than a Saturday, Sunday or legal holiday in the jurisdiction to which such notice is directed) following the day the same is deposited with the commercial carrier if sent by commercial overnight delivery service. Each party, by notice duly given in accordance therewith may specify a different address for the giving of any notice hereunder.

10.7 Assignment of Agreement. This Agreement shall be binding upon and inure to the benefit of Executive and Company, their respective successors and permitted assigns and Executive's heirs and personal representatives. Neither party may assign any rights or obligations hereunder to any person or entity without the prior written consent of the other party. This Agreement shall be personal to Executive for all purposes.

10.8 Entire Agreement; Amendments. Except as otherwise provided herein, this Agreement contains the entire understanding between the parties, and there are no other agreements or understandings between the parties with respect to Executive's employment by Company and her obligations thereto. Without limiting the generality of the preceding sentence, as of immediately prior to the Effective Time (but subject to the occurrence thereof), this Agreement shall supersede in its entirety the Employment Agreement, dated as of January 31, 2003, as amended, to which Executive and Company are parties (the "**Prior Employment Agreement**"). Executive acknowledges that he is not relying upon any representations or warranties concerning her employment by Company except as expressly set forth herein. No amendment or modification to the Agreement shall be valid except by a subsequent written instrument executed by the parties hereto. In the event that the transactions contemplated by the Merger Agreement shall be abandoned or otherwise terminated, (i) this Agreement shall cease to be of force or effect, and (ii) the Prior Employment Agreement shall remain in full force and effect.

10.9 Dispute Resolution and Arbitration. The following procedures shall be used in the resolution of disputes:

10.9.1 Dispute. In the event of any dispute or disagreement between the parties under this Agreement (excluding an action for injunctive relief as provided in Section 5.4), the disputing party shall provide written notice to the other party that such dispute exists. The parties will then make a good faith effort to resolve the dispute or disagreement. If the dispute is not resolved upon the expiration of fifteen (15) days from the date a party receives such notice of dispute, the entire matter shall then be submitted to arbitration as set forth in Section 10.9.2.

10.9.2 Arbitration. If the dispute or disagreement between the parties has not been resolved in accordance with the provisions of Section 10.9.1 above, then any such controversy or claim arising out of or relating to this Agreement, or the breach thereof, shall be settled by arbitration to be held in Chicago, Illinois, in accordance with the rules of the American Arbitration Association then in effect. Any decision rendered herein shall be final and binding on each of the parties and judgment may be entered thereon in the appropriate state or federal court. The arbitrators shall be bound to strict interpretation and observation of the terms of this Agreement. Company shall pay the costs of arbitration.

10.10 Survival. For avoidance of doubt, the provisions of Sections 4.5, 5, 8 and 9 of this Agreement shall survive the expiration or earlier termination of the Employment Period.

10.11 Headings. Section headings used in this Agreement are for convenience of reference only and shall not be used to construe the meaning of any provision of this Agreement.

10.12 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

10.13 Taxes. Executive shall be solely responsible for taxes imposed on Executive by reason of any compensation and benefits provided under this Agreement and all such compensation and benefits shall be subject to applicable withholding.

10.14 Section 409A of the Code. It is intended that this Agreement will comply with Section 409A of the Code (and any regulations and guidelines issued thereunder) to the extent the Agreement is subject thereto, and the Agreement shall be interpreted on a basis consistent with such intent. If an amendment of the Agreement is necessary in order for it to comply with Section 409A, the parties hereto will negotiate in good faith to amend the Agreement in a manner that preserves the original intent of the parties to the extent reasonably possible. No action or failure by Company in good faith to act, pursuant to this Section 10.14, shall subject Company to any claim, liability, or expense, and Company shall not have any obligation to indemnify or otherwise protect Executive from the obligation to pay any taxes pursuant to Section 409A of the Code.

In addition, notwithstanding any provision to the contrary in this Agreement, if Executive is deemed on the date of her "separation from service" (within the meaning of Treas. Reg. Section 1.409A-1(h)) to be a "specified employee" (within the meaning of Treas.

Reg. Section 1.409A-1(i)), then with regard to any payment that is required to be delayed pursuant to Section 409A(a)(2)(B) of the Code (the “ **Delayed Payments**”), such payment shall not be made prior to the earlier of (i) the expiration of the six (6) month period measured from the date of her “separation from service” and (ii) the date of her death. Any payments due under this Agreement other than the Delayed Payments shall be paid in accordance with the normal payment dates specified herein. In no case will the delay of any of the Delayed Payments by Company constitute a breach of Company’s obligations under this Agreement. For all purposes under this Agreement, reference to Executive’s “termination of employment” (and corollary terms) with Company shall be construed to refer to Executive’s “separation from service” (as determined under Treas. Reg. Section 1.409A-1(h), as uniformly applied by Company) with Company.

In addition, to the extent that any reimbursement, fringe benefit or other, similar plan or arrangement in which Executive participates during the term of Executive’s employment under this Agreement or thereafter provides for a “deferral of compensation” within the meaning of Section 409A of the Code, (i) the amount eligible for reimbursement or payment under such plan or arrangement in one calendar year may not affect the amount eligible for reimbursement or payment in any other calendar year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may be reimbursed or paid), and (ii) subject to any shorter time periods provided herein, any reimbursement or payment of an expense under such plan or arrangement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred.

10.15 Payment by Subsidiaries. Executive acknowledges and agrees that Company may satisfy its obligations to make payments to Executive under this Agreement by causing one or more of its subsidiaries to make such payments to Executive. Executive agrees that any such payment made by any such subsidiary shall fully satisfy and discharge Company’s obligation to make such payment to Executive hereunder (but only to the extent of such payment).

[Signature page follows]

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date and year first above written, to be effective at the Effective Time.

/s/ Laurie McGraw

Laurie McGraw

ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.

/s/ Lee Shapiro

By: Lee Shapiro

Title: President

Appendix A

Required Share Ownership

At all times during the Employment Period, Executive shall retain shares of Company common stock with a fair market value as shown in the following schedule. For this purpose, "fair market value" shall be determined on the first day of the applicable portion of the Employment Period by reference to the closing price of the Company common stock on such date as reported on the principal exchange on which the Company common stock is traded. Options to purchase Company common stock, restricted Company common stock and restricted stock units denominated in shares of Company common stock shall be included for purposes of determining whether these guidelines are satisfied, except that the fair market value with respect to an option shall be reduced by the exercise price with respect to such option. At the Company's reasonable request, the Executive shall provide the Company with evidence to the Company's satisfaction that the Executive is in compliance with these guidelines.

<u>During the following portion of the Employment Period:</u>	<u>Fair market value to be maintained during applicable portion of the Employment Period:</u>
From the Effective Date until the day prior to the first anniversary of the Effective Date:	100% of the Executive's Base Salary on the Effective Date.
From the first anniversary of the Effective Date until the day prior to the second anniversary of the Effective Date:	66% of the Executive's Base Salary on the Effective Date.
From the second anniversary of the Effective Date until the day prior to the third anniversary of the Effective Date:	33% of the Executive's Base Salary on the Effective Date.
From and after the third anniversary of the Effective Date:	0

AMENDMENTS TO ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. AMENDED AND RESTATED 1993 STOCK INCENTIVE PLAN (the "1993 Plan")

1. Section 6(d) of the 1993 Plan hereby is amended to add the following at the end of the first sentence thereof:

"In addition, in lieu of paying the purchase price upon the exercise of a Nonqualified Option in cash or in Common Shares of the Company, a grantee of a Nonqualified Option may pay the purchase price of the shares subject to such Nonqualified Option by authorizing the Company to withhold whole Common Shares of the Company that would otherwise be delivered to the grantee, valued at their fair market value on the date of exercise, in an amount not in excess of the aggregate purchase price (or the portion thereof elected by the grantee); provided, however, that such authority to authorize the withholding of Common Shares shall only apply in connection with the exercise of Nonqualified Options prior to the consummation of the transactions contemplated by the Agreement and Plan of Merger dated as of March 17, 2008 by and among Misys plc, Misys Healthcare Systems, LLC, Allscripts Healthcare Solutions Inc. and Patriot Merger Company, LLC (the "Merger Agreement"). Any fraction of a Common Share that would be required for the payment of such purchase price shall be disregarded and the remaining amount due shall be paid in cash by the grantee."

2. Section 15 of the 1993 Plan hereby is amended to add the following sentence at the end thereof:

"A grantee may elect to satisfy the withholding requirement in connection with the exercise of a Nonqualified Option, in whole or in part, by authorizing the Company to withhold whole Common Shares of the Company that would otherwise be delivered to the grantee, valued at their fair market value on the date of exercise of such Nonqualified Option, not in excess of any applicable withholding taxes; provided, however, that the Common Shares of the Company to be withheld may not have an aggregate fair market value in excess of the amount determined by applying the minimum statutory rate; and provided further that such authority to authorize the withholding of Common Shares shall only apply in connection with the exercise of Nonqualified Options prior to the consummation of the transactions contemplated by the Merger Agreement. Any fraction of a Common Share that would be required to satisfy such withholding requirement shall be disregarded and the remaining amount due shall be paid in cash by the grantee."

As adopted by the Board of Directors in August, 2008.

AMENDMENTS TO ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
2001 NONSTATUTORY STOCK OPTION PLAN (the "2001 Plan")

1. Section XIV of the 2001 Plan hereby is amended to add the following sentence at the end thereof:

"C. A Participant may elect to satisfy the withholding requirement in connection with the exercise of an Option, in whole or in part, by authorizing the Company to withhold whole Shares of Common Stock that would otherwise be delivered to the Participant, valued at their fair market value on the date of exercise, not in excess of any applicable withholding taxes; provided, however, that the Shares of Common Stock to be withheld may not have a fair market value in excess of the amount determined by applying the minimum statutory rate; and provided further that such authority to authorize the withholding of Shares of Common Stock shall only apply in connection with the exercise of Options prior to the consummation of the transactions contemplated by Agreement and Plan of Merger dated as of March 17, 2008 by and among Misys plc, Misys Healthcare Systems, LLC, Allscripts Healthcare Solutions Inc. and Patriot Merger Company, LLC. Any fraction of a Share of Common Stock that would be required to satisfy such withholding requirement shall be disregarded and the remaining amount due shall be paid in cash by the Participant."

2. Section V.I.(4) of the 2001 Plan is hereby deleted in its entirety.

As adopted by the Board of Directors in August, 2008.

Certification

I, Glen E. Tullman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Allscripts-Misys Healthcare Solutions, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 10, 2008

/s/ Glen E. Tullman

Chairman and Chief Executive Officer

Certification

I, William J. Davis, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Allscripts-Misys Healthcare Solutions, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's Board of Directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 10, 2008

/s/ William J. Davis

Chief Financial Officer

The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission
450 Fifth Street, NW
Washington, D.C. 20549

Re: Allscripts-Misys Healthcare Solutions, Inc.

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:

(i) this Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, which this statement accompanies, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(ii) the information contained in this quarterly report on Form 10-Q for the quarter ended September 30, 2008, fairly presents, in all material respects, the financial condition and results of operations of Allscripts-Misys Healthcare Solutions, Inc.

Dated as of this 10th day of November, 2008.

/s/ GLEN E. TULLMAN

/s/ WILLIAM J. DAVIS

**Glen E. Tullman
Chief Executive Officer**

**William J. Davis
Chief Financial Officer**

A signed original of this written statement required by Section 906 has been provided to Allscripts-Misys Healthcare Solutions, Inc. and will be retained by Allscripts-Misys Healthcare Solutions, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.